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A B S T R A C T
Forensic psychiatry inEurope isa specialty primarilyconcerned with individuals who have eitheroffended or
present a risk of doing so, and who also suffer from a psychiatric condition. These mentally disordered
offenders(MDOs)are oftencared for insecure psychiatric environments orprisons. Inthis guidance paper we
first present an overview of the field of forensic psychiatry from a European perspective. We then present a
review of the literature summarising the evidence on the assessment and treatment of MDOs under the
following headings: The forensic psychiatrist as expert witness, risk, treatment settings for mentally
disordered offenders, and what works for MDOs. We undertook a rapid review of the literature with search
terms related to: forensic psychiatry, review articles, randomised controlled trials and best practice. We
searched the Medline, Embase, PsycINFO, and Cochrane library databases from 2000 onwards for adult
groups only. We scrutinised publications for additional relevant literature, and searched the websites of
relevantprofessional organisations forpolicies, statementsorguidance of interest. We presentthe findingsof
the scientific literature as well as recommendations for best practice drawing additionally from the guidance
documents identified. We found that the evidence basefor forensic-psychiatricpractice isweak thoughthere
is some evidence to suggest that psychiatric care produces better outcomes than criminal justice detention
only. Practitioners need to follow general psychiatric guidance as well as that for offenders, adapted for the
complex needs of this patient group, paying particular attention to long-term detention and ethical issues.
© 2017 Elsevier Masson SAS. All rights reserved.
Contents lists available at ScienceDirect
European Psychiatry
journal homepage: htt p: / /www.europsy- journa l . com1. Introduction
1.1. Aims
The aim of this guidance paper is threefold: Firstly, we give an
overview of the field of forensic psychiatry (1.2–1.5). Secondly, we
provide a literature review of the evidence base and best practice
regarding the assessment and treatment of MDOs under the* Corresponding author.
E-mail addresses: birgit.vollm@nottingham.ac.uk (B.A. Völlm),
martin.clarke@nottshc.nhs.uk (M. Clarke).
http://dx.doi.org/10.1016/j.eurpsy.2017.12.007
0924-9338/© 2017 Elsevier Masson SAS. All rights reserved.following headings: the role of the forensic psychiatrist as expert
witness, risk assessment, treatment settings for MDOs, and
effectiveness of psychological and pharmacological interventions,
based on articles pertaining to reviews, randomised controlled
trials and publications on best practice (3.2–3.5). We incorporate
recommendations for best practice in forensic-psychiatric care
based on the scientific literature as well as the guidance identified.
1.2. Mental disorder and crime
Up until the 1980s most professionals believed that there was
no link between mental disorders and violence (e.g. [1]). Several
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reappraisal of this position. One example of an early study that
helped to reshape opinion is the Epidemiological Catchment Area
(ECA) study [2] a cross-sectional, retrospective survey comprising
a community sample of over 17 000 participants in five large US
cities. Based on self-report, the study found a lifetime prevalence of
violence of 7.3% in those with no psychiatric disorders whereas this
figure was 16.1% in those with serious mental illness (schizophre-
nia or major affective disorders) and rose to 35% in those with
substance misuse disorders; individuals with mental illness and
substance misuse had a lifetime prevalence of violence of 43.6%.
This suggests that, while major mental illness appears to be related
with violence, substance misuse may have a much more significant
role in increasing the likelihood of committing a violent act. This
importance of substance misuse was also shown in the MacArthur
Violence Risk Assessment Study (e.g. [3]) which followed up over
1000 patients discharged from psychiatric care and used different
methods of collating information on violence (self-report, carers’
report and criminal records). The study found no significant
difference between the prevalence of violence in patients and
others living in the same neighborhood when only looking at
individuals without substance abuse. Substance misuse raised the
rate of violence in both patients and healthy individuals but did so
disproportionately in the patient group, suggesting substance
misuse acts as a mediator between mental illness and violence.
More recently a number of meta-analyses have synthesized
data available on the relationship between mental disorders and
violence (e.g. [4–8]). These reviews, drawing on a large number of
primary studies (e.g. over 200 for schizophrenia), conclude that
schizophrenia, other psychoses and bipolar disorder are all
associated with violence. However, large variations were identified
with odds ratios between 1 and 7 for schizophrenia in males and
between 4 and 27 for females. For bipolar disorder, odds ratio
estimates ranged from 2 to 9. Importantly, for both disorders
comorbid substance abuse increased odds ratios up to threefold,
and for bipolar disorder the significant relationship with violence
disappeared when controlling for substance misuse. For all serious
mental illness diagnoses substance misuse played a more
significant role in increasing the risk for violence compared to
the illness. Personality disorders (PD) also appear to increase the
risk of violent behaviour by threefold compared to individuals with
no such disorder, and in offenders those with PD have a higher risk
of re-offending compared to those without though outcomes differ
greatly by PD type. Treated individuals, offenders and MDOs, have
improved outcomes (reduced reoffending rates; e.g. [9,10] as will
be expanded upon below). This is also the case for pharmacological
interventions which have been shown to reduce reoffending in a
national register study of 82 647 patients [11].
1.3. Forensic psychiatry
Forensic psychiatry is a subspecialty of clinical psychiatry which
requires special legal and criminological knowledge as well as
experience in the treatment of often complex and multiple mental
disorders. While the US tradition focuses on the role of the forensic
psychiatrist in the legal context and includes civil law matters [12],
European forensic psychiatry takes a slightly different perspective,
emphasising the treatment of mentally disordered offenders
(MDOs). Gunn and Taylor argue that issues of victimisation and
deprivation are essential to engage with in order to both help those
affected and to prevent future harm [13]. They define forensic
psychiatryas: “a specialty ofmedicine, based on a detailedknowledge of
relevant legal issues, criminal and civil justice systems; its purpose is the
care and treatment of mentally disordered offenders and others
requiring similar services, including risk assessment and management,
and the prevention of future victimization.” (p.1).The specialty is primarily concerned with individuals who have
either offended or present a risk of doing so, and who also suffer
from a psychiatric condition. These MDOs almost invariably have
histories of psychosocial deprivation, including poor parenting,
frequent changes in caregivers, having being in care, having
suffered abuse, poor education, and unemployment, to name but a
few [14]. They commonly have histories of substance misuse and
have often had multiple admissions to psychiatric services as well
as previous contact with the criminal justice system before coming
into forensic-psychiatric care [15].
Due to their backgrounds, namely their offending histories,
MDOs are often cared for in secure environments, either in prison
or in dedicated forensic-psychiatric hospitals. These institutions
are high cost-low volume services that may detain their clientele
for long periods of time in highly restrictive conditions (for a
review of length of stay in forensic psychiatric institutions see
[16]). The purpose of this detention is seen as twofold: care and
treatment for the patient (for their own sake as well as in order to
reduce future risk) and protection of the public from harm from the
offender. This dual role can cause dilemmas for the practitioner as
described by Robertson and Walter for psychiatry as a specialty as a
whole, though this is more acutely felt in the forensic context: “In
psychiatric ethics, the dual-role dilemma refers to the tension between
psychiatrists' obligations of beneficence towards their patients, and
conflicting obligations to the community, third parties, other health-
care workers, or the pursuit of knowledge in the field. These conflicting
obligations present a conflict of interest in that the expectations of the
psychiatrist, other than those related to patients’ best interests, are so
compelling. This tension illustrates how the discourse in psychiatric
ethics is embedded in the social and cultural context of the situations
encountered. It appears that as society changes in its approach to the
value of liberal autonomy and the ‘collective good’, psychiatrists may
also need to change”. [17] (p.228).
1.4. The role of a forensic psychiatrist
As is the case in all medical specialties, it is the medical doctor
whose duty it is to bring clinical leadership to forensic psychiatry
[18], and to have a pivotal role in defining service delivery for
MDOs and others requiring similar services on a more general level
[19]. Thus, although legal and clinical frameworks differ across
Europe, forensic psychiatrists have similar roles, such as:
 providing treatment for severely mentally ill people who offend,
 working effectively at the interface of law and psychiatry, and, in
so doing, working with other clinical and non-clinical profes-
sionals in the field,
 providing reports and giving evidence to courts, and
 assessing and managing the risk of MDOs and preventing
reoffending.
In order to fulfil these roles, forensic psychiatrists must have
specialist knowledge and skills, namely in the assessment and
management of complex mental disorders, violence and sexual
deviance,and therisksthat thesebehavioralphenomenapose. Tothis
end, the forensic psychiatrist must be able to incorporate academic
and clinical skills, techniques and research developed in neighboring
disciplines, such as youth, adult, and geriatric psychiatry, psychology
and criminology [20]. Furthermore, the forensic psychiatrist must
adapt to the role of being an objective evaluator in addition to
providing psychiatric care to patients [21]. However, although
forensic psychiatrists may cross the border from empirical medical
science into the court room and may act on behalf of courts or
administrations when they treat their patients, the patient is still at
the core of what they do. This notwithstanding, forensic psychiatrists
are interpreters of medical and psychological findings for judges,
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better understand them and apply relevant legislation accordingly. It
is vital that forensic psychiatrists are, however, aware of the risk that
their dual role could become unduly slanted towards the legal
framework they operate within, rather than by their medical ethics.
Thus, as is stipulated for all healthcare professionals, forensic
psychiatrists are ethically bound by the standards set by their
professional bodies and, indeed, judged to be guilty of misconduct if
they deviate from these standards due to pressures from the courts,
penal institutions or other societal interest groups [22]. This robust
professionalism[23,24]alsoincludesrefrainingfromcommentingon
issues beyond their expertise or that breach confidentiality.
These elements inherent in the role of the forensic psychiatrist
are even more pronounced in leadership positions. By deciding on
issues such as referral, discharge, recall and triage criteria [25,26]
and appropriate levels of security [27], directors of forensic units
are, in effect, participating in defining which behavioral issues that
society faces should be treated within general psychiatric services,
forensic services or the penal system, i.e. how society’s forensic
population is to be demarcated. To this end, forensic psychiatrists’
roles inevitably require restricting a person's liberty, at least in the
short term, and thus present the clinician and society in general
with many inherent clinical and ethical challenges. However,
ultimately, the basic aims of care delivery in forensic psychiatric
settings are essentially the same as in the community and in
medicine in general: to diminish pain and suffering and empower
the individual to function healthily and freely in society.
1.5. A European perspective on forensic psychiatry
Forensic psychiatry operates within the legal and societal
context of a country and is therefore subject to the wider influences
and trends of that society, e. g. the attitudes towards offenders—
exclusion or incapacitation on the one hand or offender rehabili-
tation on the other. Laws—rules that guide human behaviour—
differ from the scientific frameworks clinicians are otherwise used
to dealing with in that they are man-made and normative, and as
such can be changed at any time. The rules relevant to the
detention of and care for MDOs differ widely across Europe though
there is some common ground [28,29].
All European legislations recognise the concept of criminal
responsibility as a prerequisite for punishment. Individuals who
lack responsibility for the act they have committed are therefore
exempt from punishment which usually results in admission to a
treatment facility (or acquittal) rather than punishment. Most, but
not all, countries recognise some grading of that responsibility,
that is an individual is not only seen as either fully responsible or
completely irresponsible for their actions but can be of diminished
responsibility. Such diminished responsibility, where it is recog-
nised, can then result in a less severe punishment, i.e. a shorter
sentence of imprisonment.
Most European countries require some degree of reduced
responsibility for entry into the forensic-psychiatric system while
individuals with full responsibility for the crime committed will be
subject to punishment, even if they did suffer from a mental
disorder at the time of the act. However, in some countries, e.g. the
UK, access to forensic psychiatric care is independent of criminal
responsibility and determined only on the basis of the mental
condition at the time of assessment. A number of national laws
within Europe provide exclusion criteria for detention in a
psychiatric, including forensic-psychiatric hospital, e. g. personali-
ty disorders, substance use disorders or sexual deviancy. This may
be welcome from a civil liberty perspective as it means subjecting
fewer people to the restrictions of compulsory psychiatric care and
detention; on the other hand, such exclusion might also result in a
lack of service provision for those in need.Given the above, it is not surprising that rates of detention
within the EU vary widely from country to country. This is apparent
in figures of imprisonment where Eastern European countries
show imprisonment rates of over 200 per 100 000 inhabitants;
England & Wales takes the lead amongst Western European
countries with nearly 150 whilst lowest imprisonment rates are
found in Northern European countries with figures ranging from
about 40 to 70 per 100 000 [30]. Figures for forensic-psychiatric
beds are more difficult to obtain. Salize and colleagues compared
forensic bed rates in 15 EU countries and found variations from 0.8/
100 000 (France) to 13.1/100 000 (Germany) [28]. Only one other
country (Belgium) reported more than 10 beds/100 000 while six
countries indicated figures of less than 5/100 000 (Austria, Greece,
Ireland, Italy, Portugal and Spain). For Eastern European countries,
Mundt and colleagues described a mixed picture with increases in
forensic bed numbers between 1999 and 2009 in some countries
(e.g. Hungary, Poland) and decreases in others (e.g. Czech Republic,
Latvia) [31]. Chow and Priebe [32] provided more up to date figures
for eleven Western European countries describing changes in bed
numbers from 1990 to 2012. In all countries forensic bed numbers/
100 000 increased, in some cases dramatically. E.g., Austria,
Belgium, Ireland and Germany all started with less 5/100 000 in
1990 but at the end of the study period had between 8 and 12
forensic beds/100 000 population. Countries with lower numbers,
under 3/100 000 throughout, were Italy, Spain, Switzerland and
the UK. During the same period, general psychiatric beds decreased
while places in other institutions, including protected housing and
prisons, also increased though the authors could not evidence a
causal link between these different trends (which was suggested to
exist in the so-called Penrose hypothesis).
Most countries allow detention of MDOs beyond the length of
prison sentence their offence would have attracted had they been
imprisoned [33]. However, some—Croatia, Italy, Portugal—limit the
time of psychiatric detention to the time the individual would have
served had they not been mentally disordered and had received a
custodial sentence. In other countries (e.g. Germany) it is
recognised that the longer the detention in a forensic-psychiatric
facility the more relevant considerations of proportionality
become with the patients’ right to freedom being balanced against
any risk they may pose [29].
Outpatient services for forensic patients are available in some
countries though information about its use is patchy. Salize and
Dreßing [34] note that outpatient services are available in four
countries: Austria, Belgium, Germany and the Netherlands; since
their publication they have also been introduced in the UK [35] and
in Poland [36].
2. Method
We undertook a rapid review of the literature regarding the
topics relevant to this paper as described in 1.1 Aims. Rapid reviews
are an emerging form of knowledge synthesis aiming ‘to inform
health-related policy decisions and discussions, especially when
information needs are immediate’ [37]; ‘components of the systematic
review process are simplified or omitted to produce information in a
short period of time’ [38]. Despite the somewhat truncated process,
rapid reviews maintain the key steps of a systematic review in
terms of identification of a research question and search strategy
and identification, screening, selection and summarising of
relevant studies [38]; and they have been found to maintain the
essential conclusions compared to those produced by a full
systematic review [39].
We undertook a literature search based on the following
concepts: forensic psychiatry, review articles, randomised con-
trolled trials and best practice. Both textword and MeSH categories
were used as search terms in the following databases: Medline,
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conducted for a timeframe from 2000 onwards for adult groups
only. No restrictions were placed on language or publication type.
Included publications were scrutinised for additional relevant
literature, including earlier publications of interest. Please see
Table 1 for the full search strategy.
In addition to bibliographic databases, we searched the
websites of relevant professional organisations for policies,
statements or guidance of interest: European Committee for the
Prevention of Torture and Inhuman or Degrading Treatment or
Punishment, European Cooperation in Science and Technology,
European Psychiatric Association, National Institute for Health and
Care Excellence, Royal College of Psychiatrists and the World
Psychiatric Association.
We have written to the forensic sections of psychiatric
membership organisations of the EPA for comments on the topics
covered in this paper as well as to enquire about any guidance
papers that might exist on forensic psychiatry in their countries.
The response was limited and resources did not allow the
translation of national guidance documents. We have also
consulted the individual members of the Forensic Section of the
EPA, who made additional comments on content and relevant
literature as well as commented on guidance in their countries. The
final version of the paper was approved by the Board of the EPA
Forensic Section.
3. Results
3.1. Results of searches
In total, 6310 references were retrieved from Psycinfo
(n = 1377), Medline (n = 2271), Embase (n = 2265) and Cochrane
(n = 9). This was reduced to 4422 after deduplication. Initially 170
abstracts and summaries were identified for inspection, from
which 117 papers were selected for further consideration. An
additional 71 reports and papers were identified during the
website searches and downloaded for consideration.
Forty-five papers from the database searches and 16 documents
from web searches were selected for inclusion of which the main
themes were treatment/intervention (n = 25), prison psychiatry
(n = 11), risk assessment (n = 7), service provision (n = 4), commu-
nity treatment (n = 3), liaison/diversion (n = 2), European perspec-
tives (n = 2), outcomes (n = 2), ethics (n = 2), role of the psychiatrist
(n = 2) and models (n = 1). However, several papers were relevant
to multiple themes. The scientific papers and guidance papers we
identified through the searches are indicated in the references list
with one asterisk (*).
3.2. The forensic psychiatrist as expert witness
As outlined above, the role of a forensic psychiatrist may
include acting as expert witness in court, providing evidence on
issues of criminal responsibility, treatability and risk of violence.
The determination of criminal responsibility is in many countries
the most usual form of assessment requiring forensic expertise.
This typically involves the identification of any mental disorder the
examinee might suffer from and determining whether this
disorder was present at the time of the crime. Furthermore, it
will be necessary to assess the impact of the examinee’s mental
state at the time of the offence on his or her capability to appreciate
the legal wrongfulness of the act and/or his/her ability to act
accordingly [40,41]. Given the significant implications such
assessments might have for the person assessed, it is essential
that reports provided to court are carried out to high standard and
within an ethical framework [42]. Various national medicolegal
authorities [43–45] and The World Psychiatric Association haveprovided guidance on such work [46]. These include guidance on
the various stages of the process, from the request to provide a
report to gathering evidence and interviewing the examinee, the
structure of the report and the subsequent appearance in court.
Details can be obtained on the WPA website, though the key
principles of the guidance include:
 Clarity needs to be sought with regards to the details of the
request to provide a medico-legal report, including its legitimacy
and whether it falls within the expert’s area of expertise.
 The expert is obliged to provide an unbiased report and not act as
an advocate for the examinee. The WPA guidance therefore
recommends that the medico-legal expert should not be the
treating doctor of the examinee (though others having taken a
different view, e.g. [47].
 Prior to working on the report, the expert should obtain the
agreement of the examinee, based on informed consent,
including informing them of the consequences of cooperating
or not cooperating. It is important that the examinee under-
stands that the process is different to a therapeutic consultation
and that no treatment will be provided by the expert.
 Principles of confidentiality do also apply in this context and any
information not relevant to the purpose of the report must not be
disclosed.
 The report should be based on sufficient information and all
relevant information on which the conclusions rely upon should
be disclosed. It is desirable to obtain third party information.
 The assessment should be undertaken in person.
 The report should explain any medical terms used so that its
content is comprehensible to non-medically trained readers.
 Regarding the use of any instruments, including for risk, the
expert needs to be aware, and make clear in the report, their
applicability to the case assessed and any other limitations of
their use.
 Guidance is also provided as to the structure and detailed
content of medico-legal reports though it is beyond the scope of
the paper to repeat this here. Importantly, it is highlighted that a
report does not just consist of listing the facts and results of any
examinations but should provide a formulation, an explanatory
synthesis of the case, offering a biopsychosocial explanation of
the presumptive causative factors in the examinee’s offending
and risk.
 It is important that the expert highlights any uncertainties of the
case and any inconsistencies between subjective report and
objective findings and how this may impact on the final opinion.
Specific guidance regarding feigning of symptoms is provided
by Gottfried and colleagues [48]. This emphasizes the importance
of collateral information. No instruments exist to evaluate
retrospective feigning of symptoms at the time of crime, and
the use of general malingering measures such as the Structured
Interview of Reported Symptoms is recommended.
Finally, it is important for the expert to be aware that they are
there to advise the court but the ultimate decision, e.g. regarding
criminal responsibility, is determined not by the expert but by the
court.
In most work carried out as a forensic psychiatric expert
witness, it is essential to refer to the use of formal assessment tools
(see Risk). The assessment of issues such as legal and functional
mental capacity, various forms of behavioral risk and recommen-
dations for discharge, have also been rendered more amenable to
research and scientific enquiry [49] by the use of validated
actuarial and structured professional judgement tools, thus
providing a more justified basis for expert evidence and legal
decision making in the context of, arguably, increasingly risk-
conscious European societies [50,51].
Table 1
Search strategies.
Search Strategy (all searches run on 24/08/17)
Ovid 1 exp forensic psychiatry/(38376)
MEDLINE 2 forensic.ti,ab. (31050)
3 (“mentally ill offender$" or (mental adj5 offend$)).ti,ab. (606)
4 or/1–3 (66004)
5 exp guideline/or exp practice guideline/(30576)
6 (guideline$ or “best practice$").ti,ab. (245610)
7 exp Clinical Trial/(822344)
8 exp randomized controlled trials/(118140)
9 exp double-blind method/(150869)
10 exp single-blind method/(25363)
11 exp cross-over studies/(43146)
12 randomized controlled trial.pt. (475282)
13 clinical trial.pt. (529253)
14 controlled clinical trial.pt. (96050)
15 (clinic$ adj2 trial).mp. (671553)
16 (random$ adj5 control$ adj5 trial$).mp. (624463)
17 (crossover or cross-over).mp. (77353)
18 ((singl$ or double$ or trebl$ or tripl$) adj (blind$ or mask$)).mp. (208286)
19 randomi$.mp. (719887)
20 (random$ adj5 (assign$ or allocat$ or assort$ or reciev$)).mp. (202810)
21 Meta-Analysis as Topic/(16309)
22 Meta-Analysis/(84529)
23 exp Review Literature as Topic/(9683)
24 ((comprehensive$ or integrative or systematic$) adj3 (bibliographic$ or review$ or literature)).mp. (113011)
25 analy$ or metaanaly$ or “research synthesis” or “literature review”).mp. (179688)
26 or/5–25 (1606546)
27 4 and 26 (3341)
28 limit 27 to (humans and yr = “2000 Current”) (2271)
PsycINFO 1 exp forensic psychiatry/(4209)
2 forensic.ti,ab. (15482)
3 exp MENTALLY ILL OFFENDERS/(3458)
4 (“mentally ill offender$" or (mental adj5 offend$)).ti,ab. (1424)
5 or/1–4 (19081)
6 exp Treatment Guidelines/(5812)
7 exp Best Practices/(4085)
8 (guideline$ or “best practice$").ti,ab. (62114)
9 randomi$.mp. (69343)
10 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).mp. (23429)
11 placebo$.mp. (36846)
12 crossover.mp. (6514)
13 exp treatment effectiveness evaluation/(21850)
14 exp mental health program evaluation/(1996)
15 (random$ adj (assign$ or allocate$)).mp. (35339)
16 exp “literature review”/(22332)
17 ((comprehensive$ or integrative or systematic$) adj3 (bibliographic$ or review$ or literature)).mp. (31739)
18 (meta-analy$ or metaanaly$ or “research synthesis” or “literature review”).mp. (68037)
19 or/6–18 (277455)
20 5 and 19 (1735)
21 limit 20 to (human and yr = “2000 Current”) (1377)
Embase 1 exp forensic psychiatry/(12753)
2 forensic.ti,ab. (47050)
3 (“mentally ill offender$" or (mental adj5 offend$)).ti,ab. (835)
4 or/1–3 (55396)
5 exp practice guideline/(422685)
6 (guideline$ or “best practice$").ti,ab. (425150)
7 exp randomized-controlled-trial/(467945)
8 exp randomization/(75276)
9 exp single-blind-procedure/(29106)
10 exp double-blind-procedure/(142128)
11 exp crossover-procedure/(53000)
12 (clin$ adj2 trial).mp. (1381324)
13 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).mp. (262261)
14 (random$ adj5 (assign$ or allocat$)).mp. (156308)
15 randomi$.mp. (987540)
16 crossover.mp. (84299)
17 exp Meta Analysis/(132249)
18 ((comprehensive$ or integrative or systematic$) adj3 (bibliographic$ or review$ or literature)).mp. (237954)
19 (meta-analy$ or metaanaly$ or “research synthesis” or “literature review”).mp. (297871)
20 or/5–19 (2755269)
21 4 and 20 (3052)
22 limit 21 to (human and yr = “2000-Current”) (2265)
Cochrane 1 MeSH descriptor: [Forensic Psychiatry] explode all trees (209)
2 forensic:ti,ab,kw (366)
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Table 1 (Continued)
Search Strategy (all searches run on 24/08/17)
3 (“mentally ill offenders” or (mental near/5 offend*)):ti,ab,kw (43)
4 #1 or #2 or #3 (550)
5 MeSH descriptor: [Guideline] explode all trees (26)
6 MeSH descriptor: [Practice Guideline] explode all trees (16)
7 (guideline* or “best practice*"):ti,ab,kw (20551)
8 #5 or #6 or #7 (20551)
9 #4 and #8 (14)
Limited to Publication Year from 2000 to 2017, in Cochrane Reviews (Reviews and Protocols), Other Reviews and Trials (9)
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Thorough assessment of risk and protective factors is crucial for
risk appraisal and the prevention of recidivism. Risk assessments
are required both in the context of providing expertise to courts as
well as in the planning of interventions for MDOs. The risk
principle of the Risk Needs Responsivity (RNR) model necessitates
having reliable and valid risk assessments to assign individuals to
treatment programmes based on their risk [52].
Risk can be assessed using unstructured clinical assessments,
actuarial risk assessments (ARA) and structured professional
judgements (SPJ) [53,54]. Unstructured assessments are subjective
and have demonstrated poor predictive ability [54]. ARAs and SPJs
have been developed to improve the predictive validity of risk
measures. In ARA, a set of risk factors is statistically combined in a
fixed, mechanical way, often then providing a numerical outcome
regarding the likelihood of, e.g., future violence [54–56]. SPJ
approaches moved away from the reliance on static variables to
include also dynamic variables and give professionals the
flexibility to modify the overall risk level [57]. Dynamic factors
may be amenable to treatment and therefore SPJs can be used to
identify and inform treatment targets. For example, the Violence
Risk Scale (VRS) (e.g., [58]) contains six static and 20 dynamic risk
factors. The HCR-20 (now Version 3; [59]) contains 10 static,
historical factors and 10 dynamic factors, five pertaining to recent
clinical functioning and five considering future risk management.
Empirical evidence suggests that both ARA and SJP perspectives
have similar predictive validity [56,60]. Coid and colleagues drew
similar conclusions but also found that, in respect to men, actuarial
measures outperformed SPJs in predicting violent reoffending [61].
Pre-treatment ratings on the dynamic factors can be used to
represent treatment targets and post-treatment ratings can be
used to assess progress, but only if these dynamic factors not only
have predictive validity but changes in these factors tap into the
causal mechanism of criminal behaviour and result in changes of
behaviour [62]. Causal instead of predictive models should
therefore be preferred in the implementation of clinical risk
management [63].
There are a large number of specific risk assessments tools in
use. A systematic review of the literature [64] identified 80
different variables used in the measurement of violent or sexual
recidivism and 20 formal assessment instruments. A review of
surveys on the use of violent risk assessment tools, published
between 2000 and 2013, identified nine surveys, mostly from the
US and the UK [65]. A more recent global survey of 44 countries
reported the use of 400 instruments [55]. The HCR-20 (Version 2
[66]; Version 3 [59]) was identified as the most commonly used
instrument both in Europe and internationally in both studies,
followed by the Psychopathy Checklist Revised (PCL-R) [67].
A meta-analysis of violence risk assessment tools, reviewing 68
studies pertaining to nine different risk assessment tools, found
that the Psychopathy Checklist Revised (PCL-R) produced the
lowest rate of predictive validity; however, it is of note that this
instrument was designed as a clinical rather than a risk assessmenttool [68]. The highest rates of predictive validity were found in
instruments designed for specific rather than more general
populations, e.g. for sex offenders, and in older and in predomi-
nantly white samples [68]. Additionally, neither ARA nor SPJ
measures produced better levels of predictive validity. However,
from a clinical point of view, the flexibility afforded by SPJ
approaches along with its potential utility in treatment planning
has led to a preference of practitioners of these approaches. In
criminal justice settings, the picture is slightly different though,
with ARA measures being used more widely, in particular in the
assessment of sex offender risk [69]. For sex offender risk
assessment, this preference is supported by a review of 118
prediction studies [70], concluding that ARA measures out-
performed SPJ approaches in the prediction of sexual recidivism.
There are concerns about the high number of false positives—
individuals who incorrectly are considered having a high risk of
reoffending—which may lead to additional treatments or restric-
tions to liberty. Consequently, a further systematic review explored
the predictive accuracy of the most commonly used risk
assessment instruments [53]. The review found that tools are
effective at screening out individuals at low risk of reoffending but
only have low to moderate positive predictive value [53]. Fazel and
colleagues stated that “even after 30 years of development, the
view that violence, sexual, or criminal risk can be predicted in most
cases is not evidence based.” (p.5) [53]. The review concluded that
the tools perform moderately well for informing treatment but are
limited if used as the sole determinant of sentencing or release
decisions [53]. The need to be cautious in the use of risk
assessment instruments for individual clinical decisions is com-
pounded by the low and varying base rates for violent recidivism in
the local population of which the assessed person is a member and
the assessed person is compared with [71]. Caution is also
warranted in the application of risk assessment tools in specific
populations such as women (e.g. [72]) or those with intellectual
disability [73] as psychometric properties might vary across
groups.
Forensic risk assessment models generally focus on risk rather
than protective factors [74,75]. Therefore, others have sought to
emphasise protective factors [76]. For example, the 17-item
Structured Assessment of PROtective Factors for violence risk
(SAPROF) [77,78] was developed to be used alongside the HCR-20.
The SAPROF may also have predictive validity for sexual offending
as well as other violent offending although more evidence is
required [79]. Although their predictive validity seems not to
outperform the validity of risk focused assessment tools, strength
based tools may improve the predictive validity of risk oriented
approaches and contribute to the desistance from crime [79].
Consideration of protective factors is consistent with clinical
practices such as rehabilitation and recovery and may have a
positive effect on the motivation to participate in treatment [57].
This consideration is underlined by a study from Abbiati and
colleagues [80] in which, in contrast to previous findings, none of
the subscales of the SAPROF showed predictive validity, except for
‘Motivation’. Although the use of protective factors in assessing risk
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that the relevance of these factors can be found elsewhere, like the
development of a therapeutic relationship, the influence of
protective factors deserves more scientific attention [81].
Violence risk assessment is a global phenomenon, yet its utility
in clinical practice has not been evaluated thoroughly. E.g., Singh
et al’s survey found that, overall, raters received feedback about the
outcome of their assessments in fewer than 40% of cases; where
assessments were completed to inform management plans,
feedback was available in fewer than 50% of cases and only in a
third of cases were the plans implemented [53]. Obviously, risk
assessments will only reduce violence if they are communicated
and related plans implemented. More research is therefore needed
regarding any obstacles in these areas. It also remains largely
untested as to whether embedding risk assessment and formula-
tion into clinical care prevents recidivism; the only RCT in this area
so far [82] suggests this may not be the case.
3.4. Treatment settings for mentally disordered offenders
Treatment for MDOs is provided in a number of settings—in the
community, either as diversion from custodial sentences or
following release, in secure forensic-psychiatric hospitals of
different security levels, and in prison. Some countries have
developed diversion schemes which allow for he early detection of
mental disorder, e.g. at the time of arrest or at appearance in court
[83]. This will then allow to either divert the person to the health
system without the involvement of the criminal justice system or
for the court to take the individual’s mental health needs into
account when dealing with the case. Liaison and diversion
services,1 usually staffed by mental health nurses and based
either in police stations or at court, provide screening, assessment
and onward referral, or in some cases further support and
management. Such schemes have been found to improve mental
health and reduce the risk of re-offending and are therefore
recommended for implementation (for a review see [83,84].
Effective coordination of the different agencies involved is key to
the success of these services [85].
3.4.1. Treatment in the community
In the community, individuals with offending histories should
have access to the same services as their non-offending fellow
citizens though some aspects of this treatment may not be
voluntary. For example, individuals may serve a community
sentence with the requirement to attend for mental health or
substance misuse treatment. Equally, there are those who are
released on licence (conditionally released) and part of their
licence conditions may be to attend for particular treatments.
The importance of community services for MDOs is demonstrat-
ed by studies investigating the prevalence of mental disorders in
offenders in the community. Looking at probation supervisees at
various stagesof engagement, Brookerand colleaguesfound that 15%
had contact with mental health services in the preceding 12 months
and 27% had been seen by mental health services at some point in
their lives [86]. Furthermore, an assessment of needs in probation
service areas and prison establishments in England and Wales found
45% of offenders had emotional well-being needs [87].
However, there are some challenges in providing psychiatric
services for offenders in the community. Firstly, many have a
complex mixture of social disadvantage as well as psychiatric1 In the US a similar development took place with the introduction of Mental
Health Court but to our knowledge no such courts exist in Europe, although they
have been piloted in the UK (www.ohrn.nhs.uk/resource/policy/MentalHealth-
Courts2010.pdf).problems [88] and, in common with other such socially and
psychiatrically disadvantaged populations, they either do not
access available services or, if they do so, such access is
intermittent and crisis driven following an overdose or injuries
received in a fight [89]. For instance, Brooker et al found that nearly
39% of offenders had visited an accident and emergency
department or an NHS walk in centre at least once in the previous
12 months [86]. Secondly, in countries where services are
diagnostically defined, MDOs may be disadvantaged as they may
present with a range of sub-threshold pathologies which may not
meet the service criteria for individual services. For instance, they
may have had brief psychotic episodes, but not schizophrenia, and
hence may not be accepted by a Community Mental Health Team.
Similarly, they may have borderline intelligence or mild learning
disability with not severe enough problems to meet criteria for
learning disability services. The same is the case for substance
misuse where MDOs may abuse a range of substances without
developing dependency for any specific one and therefore they
may not be able to access substance misuse services. In addition,
MDOs often suffer from personality disorders, a diagnosis
sometimes excluded from psychiatric services though changes
have been made in this respect in recent years [90].
It is not clear which model works best for MDOs in the
community and whether compulsion produces better outcomes.
Given the complex needs of MDOs, assertive outreach models
(Assertive Community Treatment, ACT) of care have been applied
to this patient group. Jennings reviewed the evidence of such
models, adapted for forensic populations, and concluded that there
was evidence for improvement in mental health but not offending
outcomes [91]. They recommend the provision of extended
residential treatment with a focus on life skills and treatment
continuity prior to implementing ACT. A recent systematic review
of ACT trials, including 11 studies (3 RCTs, none based in Europe)
also found only limited support that ACT adapted for forensic
populations improves forensic outcomes [92].
Community treatment orders (CTO) allow for compulsory
treatment in the community, usually following discharge from a
hospital setting. However, research has failed to produce
convincing evidence that CTOs are superior to treatment as usual
in terms of readmission rates and other health outcomes (for a
review see e.g. [93,94]) and Kisely and colleagues found that 238
CTOs would be needed to prevent one arrest [95].
3.4.2. Treatment in forensic-psychiatric in-patient settings
While provision of care in psychiatric settings is considerably
more resource intensive than in prison, there is some evidence
from a systematic review of patient outcomes following discharge
from secure psychiatric hospitals that reoffending rates are lower
when compared to released prisoners [96]. Nevertheless, the major
predictors of recidivism in MDOs have been shown in a meta-
analysis to be the same as for non-MDOs [97] suggesting that
general criminogenic needs might be more relevant in predicting
outcome than mental disorders.
While it is possible for MDOs to be treated in general psychiatric
settings in many countries, they are usually admitted to specific
forensic-psychiatric settings. A number of countries have found
forensic treatment beds to reduce in number, others have
described an increase [98]. In England and Wales, e.g., the
forensic-psychiatric population has increased by 45% between
1996 and 2006 and the length of stay has also risen. A recent study
found that up to a quarter of patients could be classified as ‘long-
stay’ (length of stay more than 10 years in high or more than 5 years
in medium secure care) and some have little prospect of being
released which poses significant ethical issues [99]. Most countries
provide forensic care at different levels of security, reflecting the
risk the patient poses [28]. While such levels of care can facilitate
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lead to inefficiencies and waiting times, particularly where these
different security levels are provided in completely separate
institutions as is the case, e.g., in England & Wales.
Services may also differ in terms of the patient groups they cater
for. While in the Dutch forensic-psychiatric system the majority of
patients are diagnosed with a personality disorder, other countries
have been more reluctant to cater for this group. In England and
Wales a pilot service was developed in the early 2000s for
individuals with so-called Dangerous and Severe Personality
Disorders, established partly in prison and partly in high secure
hospitals [100]. However, this service has now been decommis-
sioned and there is an expectation that interventions for
personality disordered offenders are provided within the criminal
justice system.
Given the complexity of presentations of MDOs, the assessment
of the effectiveness of treatment in such institutions is also highly
challenging. In addition to specific interventions, which will be
addressed below, attention has to be paid to the therapeutic milieu of
the institution itself.Giventhe nature of thepopulation,security isan
important element of care and can be divided into structural or
environmental, procedural and relational aspects [101]. Tapp and
colleagues undertook a Delphi survey to identify the key elements of
high secure care [102]. In addition to the different elements of
security, experts reached consensus on some specific medical
(clozapine), psychological (CBT based interventions) and social
interventions (e.g. off-ward activities) as well as general elements of
care delivery (multidisciplinary working, patient involvement)
making a positive contribution to care in round one of the survey.
However, no consensus was reached on which of these aspects are
essential elements of care in any of the subsequent survey rounds.
The same author group undertook a systematic review of high
secure care [103] identifying 22 studies (13 European). Evidence for
effectiveness was found for high secure care itself, third wave
cognitive-behaviourally based interventions, psychoeducation and
antipsychotic interventions; however, the evidence base is weak
given that mainly small, single, non-RCT studies contributed to the
review.
3.4.3. Prison psychiatry
Even in countries where specialised institutions exist that
allow for the redirection of MDOs from the criminal justice to the
healthcare system, most offenders with mental disorders are
found in prison settings. The high prevalence of mental disorders
has been described in numerous studies from different countries.
Fazel and Danesh synthesized the findings from 62 surveys
including nearly 23 000 prisoners from 12 countries, including
nine in Europe [104], and found that 3.7% of men (4% of women)
had a diagnosis of psychotic illness, 10% of major depression
(12%), and 65% of PD (42%, mainly antisocial PD)—rates much
higher than those in the general population. For substance related
disorders, based on 13 studies (though only three based in
Europe) including over 7 500 prisoners, estimates for alcohol
abuse or dependence ranged from 18 to 30%, and for drug abuse/
dependence from 10 to 48%. The increased risk of suicide in
prisoners is of particular concern and is the leading cause of death
in penal institutions, especially during the early stage of
confinement. An updated systematic review of the prevalence
of psychotic illness and major depression examined 109 samples
(38 European) including over 33 000 prisoners from 24 countries
(14 European) [105]. Overall, similar prevalence rates were found
although there was an increase over time in depression in the
USA. Suicide rates per 100 000 prisoners have been found to range
from 58 to 147 in a review of studies from 12 studies from
Western countries (9 European) compared to figures from 16 to
31 in the general population [106].Prisons are arguably places not conducive to mental well-being.
Imprisonment is by its very nature and design associated with the
deprivation of liberty, restrictions to one’s life style and autonomy,
a loss of employment and accommodation, and, importantly, of
relationships, including with partners, parents and children. The
environment itself may be perceived as harsh and unsupportive
and some prisoners, in particular those with sexual offences, may
experience bullying and victimization [107]. All these factors
contribute to an increase or exacerbation of mental health
problems in prisons and therefore call for the implementation
of services to address these issues [108].
Whether or not mentally disordered persons should be treated in
prison or hospital is a primarily philosophical question and different
countries have developed a range of approaches to dealing with the
issue of mental disorder and imprisonment. As described above,
countries applying the construct of criminal responsibility can
prevent mentally disordered persons from being imprisoned and
instead divert them to the hospital system. Whether or not transfer of
prisoners to a hospital setting is possible depends largely on the legal
system of the country. Treatment of an acutely psychotic prisonercan
in principle take place within a prison hospital or ward or via transfer
to a general or forensic psychiatric hospital. Most European countries
rely on a number of these options [109] though some have one option
available only (e.g. treatment only in prison hospitals in Belgium and
Lithuania or exclusively via transfer to a forensic-psychiatric hospital
in Ireland).
For those prisoners treated within penal institutions (whether
or not hospitalized within the prison system), the principle of
‘equivalence’ with therapeutic provision matching that of care in
the community according with the development of psychiatric
care in each country, should prevail as has been mandated by a
number of European and international conventions and recom-
mendations though it is doubtful whether the majority of
prisoners with mental disorders receive such care. In addition to
funding and organisational issues, there are also challenges with
regards to the evidence-base of treatments in prisons, not least due
to the significant hurdles associated with running trials in these
settings [110].
A number of international rules are applicable to the treatment
of prisoners. Of these the United Nations Standard Minimum Rules
for the Treatment of Prisoners [111] as well as the UN Convention
on the Rights of Persons with Disabilities [112] are of most
relevance worldwide. Within Europe, the Council of Europe has
developed recommendations on the ethical and organizational
aspects of healthcare in prison (Recommendation No R (98) 7)
[113] while the European Prison Rules (Recommendation Rec
[2006]2) [114] specify that prison conditions must not infringe
human dignity; life in prison should approximate life in the
community (including equivalent healthcare) with restrictions
only applied to the minimum necessary. Furthermore, prisons
should offer meaningful occupational activities and treatment
programmes, preparing for reintegration into society. The Europe-
an Committee for the Prevention of Torture and Inhuman or
Degrading Treatment or Punishment [115] visits places of
detention, including prisons, and has also developed some
standards for prison, e.g. regarding health-care provision, living
space per prisoner, solitary confinement and the situation of life-
sentenced prisoners.
In addition, a number of professional organisations have
developed guidance documents touching upon prison psychiatry,
though these are by their nature recommendations and not legally
binding, e.g. the WorldMedical Association(esp.Declaration ofTokyo
1975) [116], the World Psychiatric Association (esp. Declaration of
Hawaii 1977) [117] and the International Council of Prison Medical
Services (Oath of Athens) [118]. More detailed guidance for doctors
working within the prison system is available in the consensus paper
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Psychiatric Association [119,120] which stipulates:
 The principle of equivalence must prevail—prisoners must not be
discriminated against for being imprisoned and hence should
have access to specialist mental health treatment—based on a
multidisciplinary team approach—including pharmacological
and psychological interventions, day-care, substance misuse
treatment and in-patient treatment.
 Individuals should not be excluded from accessing such
treatment on the basis of specific diagnoses or behaviour
associated with such diagnoses, e.g. personality disorders or
substance misuse.
 Prisoners with serious mental disorders should either be
transferred to a suitable treatment facility outside prison or
treated in a hospital wing within the prison.
 All prisoners should be screened for mental disorders, including
substance misuse, using a recognised, standardised tool, upon
reception by appropriately trained personal following a written
procedure which outlines what actions need to be taken as a
result of the screening as necessary.
 Except for in emergency situations, consent to treatment must be
sought and prisoners who have the capacity to make informed
treatment decisions must not be treated against their will. This
includes situations of self-inflicted harm, including hunger strike.
 Coercive measures, including forced medication, restraint,
seclusion and solitary confinement must be reduced to an
absolute minimum. Clinicians must not use any of these
measures as a form of punishment and individuals subject to
coercive measures must be closely supervised to identify any ill
effects of the intervention. The use of these measures should
follow written policies and procedures and be documented and
monitored (see also [121]).
 Principles ofconfidentialityalsoapply toprisonersandthetreating
physician must not disclose confidential information to the prison
authorities or any other agencies without patient consent unless
there is a clear legal provision to do so within the country.
 Mental health teams in prisons should carefully plan for a
prisoner’s release by making links to community services in good
time and arrange for a full handover to take place.
 Prisons should consider the specific needs of vulnerable or
marginalized groups which may have specific mental health
needs, including women, ethnic minorities, immigrants, juve-
niles and sex offenders.
 The prison should be committed to mental health promotion and
training of staff to raise awareness of mental health issues and to
minimise stigmatisation (see also [122]).
Specifically for the prevention of suicide, the International
Association for Suicide Prevention Task Force on Suicide in Prison
[123] has developed recommendations which provide helpful
guidance, emphasizing the need for training correctional staff to
recognise suicide risk, the importance of the general prison
environment, including initiatives to reduce victimization, good
communication between staff and inmates, procedures for
screening inmates for suicide risk and for the observation of
suicidal inmates, adjustments to the built environment, e.g.
removal of ligature points, procedures for the distribution of
medication, debriefing after a suicide has occurred, and providing
sufficient resources for an effective suicide prevention strategy.
3.5. What works for mentally disordered offenders
Caring for MDOs requires simultaneous consideration of: a) the
needs for treatment resulting from specific elements of the mental
disorder and b) the needs for treatment with respect to factorspromoting criminal behaviour. Therefore, treatment programmes
require multiple components to address the complex needs of
MDOs [124]. However, people are exposed to various treatment
agents and environmental influences and so it may not be feasible
to conduct rigorous controlled studies to assess the efficacy of
specific treatments [124].
3.5.1. Psychological interventions
Correctional treatment was viewed negatively in the 1970s when
the findings from Martinson’s paper “What works?” [125] contribut-
ed to the popular view that “nothing works”, a view which endured
through the 1980s [126]. Treatment programmes for MDOs are
informed by programmes for non-mentally disordered offenders and
thisevidence base at the timewas limited. Treatment programmesfor
MDOs in secure settings were poorly designed, implemented and
evaluated [127]. Since then, evidence has been provided for violence
reduction programmes and sexual offending programmes though in
particular the evidence for the latter is hotly debated still, and some
argue the investment is not justified given the relatively narrow
margin of difference compared to non-treated populations.
The risk-need-responsivity (RNR) model [52,128] has been an
influential model of offender assessment and rehabilitation. As
suggested by its name, it is based on three principles: 1) the risk
principle asserts that criminal behaviour can be reliably predicted
and that treatment should focus on higher risk offenders; 2) the
need principle highlights the importance of criminogenic needs in
the design and delivery of treatment; and 3) the responsivity
principle describes how the treatment should be provided. Despite
the evidence base for the principles of the RNR model in reducing
recidivism, treatments for MDOs often do not adhere to its
principles [129]. Therapies are often adapted in content or delivery
style to meet the needs of individuals or groups of individuals
[130]. These adaptations fit with RNR principles but heterogeneity
can make evaluating the efficacy of such therapies more difficult. In
addition, manualised treatments can restrict the ability to address
the responsivity principle [131].
Other models include the strengths-based good lives model
(GLM), which focuses on improving how the offender functions as
a person by enhancing his or her capabilities to attain goals, or
primary human goods, through socially acceptable means
[132,133], and is applicable for MDOs [74,134]. Andrews and
colleagues defended the principles of the RNR model and rebutted
criticism of the model by proponents of the GLM model [135]. For
example, they argue that the RNR model does consider motivation
and the strengths of the offender.
A number of reviews have addressed the effectiveness of
psychological interventions for MDOs, focusing on outcomes
related to antisocial and offending behaviours. McGuire reviewed
interventions for reducing aggression and violence and concluded
that personal violence can be reduced by psychosocial interven-
tions which include approaches such as social problem-solving
and interpersonal skills [136]. The RNR model was advocated to
improve targeting [136]. McGuire called for more RCTs to improve
the evidence base but also highlighted the need for practical trials
[136]. RCTs should be registered at inception and reported to a
sufficient standard [137].
A more recent review of interventions for reducing aggression
and violence found that modified forms of Reasoning and
Rehabilitation (R&R) in forensic settings had completion rates
approaching 80%, and that R&R and Cognitive Behaviour Therapy
showed the most promise [138]. However, outcomes are often
assessed over short periods and there is little evidence of the
long-term outcomes [138]. The one, small scale, RCT of a R&R
cognitive skills programme for MDOs within Rampling and
colleagues’ review found lower levels of verbal aggression but no
difference in violence compared to MDOs who received treatment
B.A. Völlm et al. / European Psychiatry 51 (2018) 58–73 67as usual (TAU) [139]. However, half did not complete treatment
and completers fared better than non-completers [139]. Other
authors have described that starting but not completing
treatment results in worse outcomes than never starting
treatment at all [9,10].
Therapies which help to improve an individual’s engagement
and communication skills can be beneficial before addressing
offence related programmes. For example, cognitive remediation
therapy has been shown to improve working memory, processing
speed and attention in people with schizophrenia [140]. Other
therapies such as music therapy, which encompasses a variety of
music making interventions, have been associated with improve-
ments in communication, social skills and confidence [141,142]. For
example, prisoners who have not engaged in other therapies have
participated in music therapy but its efficacy has not been
evaluated in an RCT [142].
A systematic review of interventions for women offenders
found that interventions which address early trauma and
comorbid substance misuse had the most utility [143]. Bartlett
and colleagues described the need for more robust evidence and
more studies of community settings where most women offenders
are based [143]. Moloney and Moller outlined good practice on the
mental health of women in prison settings and also identified the
importance of trauma-focused work to help meet the needs of
women [144].
Looking at interventions for specific offences, the CBT-based Sex
Offender Treatment and Evaluation Project (SOTEP; [145]) was
well-designed, comprehensive and long-term, yet, found no
difference in the rate of reoffending between the treated and
the control group [146]. Post-hoc analyses found that individuals
who met the SOTEP programme’s treatment goals had lower rates
of reoffending than those who did not [147]. However, systematic
reviews of psychological interventions for sex offenders have
called for more methodological rigour [146,148,149] and further
randomised trials [146]. Recommendations included not including
people who have dropped out of treatment as controls [148]. A
meta-analysis of psychological treatments for sexual offenders
against children found studies with acceptable methodologies did
not provide evidence of treatment efficacy and poor quality studies
raised the effect size [149]. A Cochrane Review of psychological
treatments for sex offenders identified ten studies involving 944
men although some excluded MDOs [146]. However, little
information was available on the primary outcome of reoffending.
The follow-up periods were generally short particularly given that
sex offenders have low rates of reconviction and need to be
followed up for sufficient time. A recent review of the prison-based
Core Sex Offender Treatment Programme (SOTP) on the re-
offending in England and Wales reported disappointing findings
with little or no difference in reconvictions between treated and
untreated sex offenders. Mews and colleagues found that treated
sex offenders were significantly more likely than matched controls
to be reconvicted of a sexual offence and more likely to be
reconvicted of a child image offence, with an average follow-up of
8.2 years [150].
Interventions aimed at specific disorders have been reviewed in
a number of meta-analyses. For example, Yoon and colleagues
identified a modest effect for CBT and mindfulness-based therapies
for depression and anxiety in prisoners [151].
A review of 27 RCTs of psychological treatments for people
with personality disorder found some evidence of positive
improvements with DBT, emotion regulation group interventions,
and psychoanalytically oriented partial hospitalisation for bor-
derline PD [152]. There was also some evidence for CBT for
avoidant PD and brief adaptive psychotherapy, short-term
dynamic psychotherapy, and manual-assisted CBT treatment
for mixed PD [152]. However, Duggan et al. noted there was muchvariability in what constitutes TAU [152]. Such methodological
differences and sample heterogeneity restricted [152] or pre-
vented [130] meta-analyses being conducted. Consensus on
suitable outcome measures would improve the comparability
of studies [130]. A more recent review found less evidence in
support of treatments for Antisocial Personality Disorder (AsPD)
but Wilson and colleagues cautioned about viewing the disorder
as untreatable due to the low sample size and likely insufficient
power [153]. NICE guidance sets out principles for working with
people with AsPD such as having clear pathways in order to
provide the most effective multi-agency care [154,155]. However,
others have called for more emphasis on the therapeutic
relationship [155,156]. While some evidence reviewed in this
section has been based on non-offending samples, recommen-
dations such as the importance of therapeutic relationships
justify their inclusion. Non-completion of psychological treat-
ments for people with personality disorder, particularly border-
line PD, is particularly problematic [157]. Strategies are required
to build a good therapeutic alliance and different strategies may
be required for different disorders [157].
The treatability of psychopathy remains inconclusive [158]. It
is essential to evaluate the efficacy of treatments, especially in
new services. In England, the government established four pilot
sites for offenders with Dangerous and Severe Personality
Disorders (DSPD), two in high secure prisons and two in high
secure hospitals. Each pilot site was allowed to determine its own
treatments. Burns and colleagues, as part of one of the
commissioned evaluations of the DSPD service, identified more
than 20 different treatments offered across the four sites [159].
All sites offered psychoeducation and psychological skills based
treatments. Individuals usually participated first in psycho-
education programmes in order to help the individual understand
their personality disorder and become familiar with group work
prior to addressing any offence related programmes. However,
not all sites offered programmes to address specific types of
offending (e.g. sex offences). Criticisms of the DSPD initiative
included the initiative being implemented without a consensus
on what works [159] and for not selecting one intervention to test
in a randomised trial across the hospital and prison pilot sites
[160]. Further, follow-up studies were not possible because of the
limited time period [161]. The DSPD service has been decom-
missioned without investigating the post-discharge outcomes of
these patients and prisoners. A new offender personality pathway
strategy has been implemented in England, placing more
emphasis on treatment within the criminal justice as opposed
to healthcare system [162]. Again, this was implemented without
a thorough evaluation of the evidence base.
Not all treatment modalities have been applied to MDOs; Knabb
and colleagues reviewed ten treatment modalities and found many
had not focused on MDO populations or were not able to address
the many complexities [163]. However, the generalisations
suggested by Blackburn for effective treatment programmes for
MDOs remain valid. MDOs present with complex problems which
require individualised assessment and treatment formulations and
therefore treatment programmes need to have multiple compo-
nents to address these problems [124]. Conditions are long-term,
requiring continuity of support from secure care and into the
community [124]. Treatment should also attend to the individual’s
social functioning and quality of life [124].
3.5.2. Pharmacological interventions to reduce aggression
Research indicates that staff on forensic wards are exposed to
aggressive behaviour at least to the same extent as staff on acute
psychiatric wards, with unprovoked aggression being particularly
prevalent [164]. Preventing aggressive behaviour and the phar-
macological treatment of agitation are key elements guaranteeing
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agitation and aggression in forensic patients should take into
account the nature of this group of patients characterised by a
chronic course of the disease, long-lasting stays in hospital,
complex morbidity and prior aggressive behaviours. Clinical
practice indicates that agitation and aggression in this group of
patients may be related to a number of factors, including
exacerbation of psychotic symptoms, e.g. as a result of discontinu-
ation of medication, drug resistance, impulsive reactions in people
with organic central nervous system dysfunction or in those with
personality disorders, somatic conditions, or the use of psychoac-
tive substances. Specific factors related to detention in forensic-
psychiatric facilities, such as long-lasting hospitalization,
conditions of isolation and restriction, uncertain length of stay
in hospital and overcrowding also contribute to the escalation of
conflicts in the group of patients in long-term confinement.
There is limited research and guidance available regarding the
effectiveness of drug treatment in aggression; of relevance here is
the National Institute for Clinical Excellence (NICE) guidance on
the treatment of violence and aggression though this focusses on
short-term management and is not specific to forensic settings
[165]. A Cochrane review outlined the evidence for the treatment
of aggression and associated impulsivity with antiepileptics [166].
Further guidance is available on the pharmacological treatment of
antisocial and borderline personality disorders as described below,
though, again, recommendations do not take forensic settings into
account separately. Guidance on drug treatment of sex offenders
will also be referred to below. Due to this lack of guidance specific
to forensic patients, we draw here inferences from the research and
guidelines relating to non-forensic patient populations also.
3.5.2.1. Short-term management of aggression. In relation to
patients who are acutely agitated and might become aggressive,
non-pharmacological interactions, including, in particular,
attempts of verbal deescalation or providing an appropriate safe
environment should be applied as the first-step procedure;
however, if ineffective, pharmacological interventions are
recommended [165]. Such acute interventions, often referred to
as rapid tranquillisation, aim to calm the patient down without
causing sleepiness [167]. Pharmacological treatment commenced
early may prevent the application of physical restraint or seclusion,
which is traumatic for most patients [168], and may also reduce the
risk to staff caring for the patient [169].
First and second generation antipsychotics, benzodiazepine
derivatives (BZDs), their combination and other sedatives have
been used in the acute pharmacological treatment of aggression.
As with other drug treatment, when choosing the appropriate
medication, the patient’s somatic condition and coexisting
diseases have to be taken into account; a sudden deterioration
in the general medical condition, including side effects of
antipsychotics (e.g. carbohydrate management disorders, electro-
lyte imbalances, or malignant neuroleptic syndrome), and drug
interactions have to be considered as the cause of the agitation.
Further considerations include the method of drug administration,
the speed of onset of the sedative effect and, if possible, the
patient’s preference [170].
None of the medications fulfil all the criteria of an ‘ideal’ anti-
agitation medication though recommendations can be made on
the basis of effectiveness, tolerability and safety. The recent NICE
guidelines on the short-term management of aggression, based on
a thorough systematic review of the literature, recommend the use
of intramuscular lorazepam or intramuscular haloperidol together
with intramuscular promethazine for rapid tranquillisation [165].
It of note that there is no evidence for superior efficacy of the
combination of haloperidol and benzodiazepines over the use of
one of these drugs alone. Lorazepam is to be used as first choice,particularly if little is known about the patient or they have not had
antipsychotic medication before. In people diagnosed with
cardiovascular disease or with risk factors of QT prolongation
the application of haloperidol and promethazine should be
avoided. Previous guidance [171] also supported the use of IM
olanzapine which has been found to be effective but carries a risk
of serious interaction effects if given concomitant to BZDs
(including, among others, hypotension, bradycardia and respira-
tory depression) [172].
BZDs are widely used in treating agitation resulting from
stimulant intoxication, ethanol withdrawal, or when the aetiology
of agitation is undetermined. Before using benzodiazepines
attention must be paid to the risk of respiratory depression and
hypotension, in particular in people with respiratory conditions or
those with alcohol intoxication. Therefore, for agitation associated
with alcohol intoxication, some experts recommend the use of FGA
or SGA over BZDs [172].
After rapid tranquillisation it is necessary to monitor the
patient’s level of consciousness, and monitor basic observation
parameters, including heart rate, blood pressure, temperature and
respiration rate, as well possible side effects of the medications
used. In forensic (and other) settings rapid tranquillisation might
be used alongside other restrictive measures such as manual or
mechanical restraint or seclusion. Particular attention is to be paid
to observations in these circumstances and restraint in the prone
position should be avoided. Individuals placed in seclusion should
be observed continuously.
The difference in utilization of non-pharmacological restrictive
measures across Europe warrants particular mention; e.g. in the
UK the use of mechanical restraint is a rare exception [173] while
other countries rarely use seclusion [174]. There seem to be
cultural differences at play here as the evidence base to support the
use of one over the other of these measures is weak and findings
relating to patient preference are also mixed [175].
3.5.2.2. Pharmacological prevention of aggression. In addition to
managing acute aggression, pharmacological interventions are
used to prevent the occurrence of aggression in the context of
different mental disorders. While the evidence and guidance in
this area is to a large extent reflective of good clinical management
of specific psychiatric disorders, we would like to highlight here
the evidence in relation to the treatment of disorders and
symptoms particularly associated with aggression. Such
treatment does not only benefit patients but it has also been
demonstrated that pharmacological treatment of psychosis in
prison reduced violent recidivism [176].
Data from numerous studies indicate that the risk of aggressive
behaviour in people suffering from psychotic disorders is
significantly higher than in the general population as described
above. In the group of patients suffering from schizophrenia
spectrum disorders (SSDs) pharmacological treatment may
therefore reduce the risk of violence [177,178]. The majority of
available data relates to the use of antipsychotic medications, first
and second generation antipsychotics, and relevant guidelines for
these disorders should be followed; with regards to the safety
profile, the use of SGA seems preferable though some have
questioned this conclusion [179–181]. In choosing antipsychotic
medications, the anticholinergic burden should also be taken into
consideration. Most antipsychotic medications have anticholiner-
gic properties [182], which has been shown to have a detrimental
effect on global cognition and limiting the patients’ functional
capacity and ability to participate in and benefit from psychosocial
treatment programmes [183,184] thus potentially prolonging
patients’ lengths of stay. Pharmacological interventions should
be supported by psychoeducational approaches. Data in forensic
settings supports the use of adherence therapy [185] to build
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relapse due to stopping the medication [186] particularly as non-
adherence to antipsychotic medication has been associated with
criminal recidivism [187]. Alternatively, depot medication has
been shown to support compliance and promote regular service
contact in forensic outpatients with a history of non-compliance
and aggression [188].
A significant percentage of patients in forensic psychiatric
settings suffer from reduced impulse control and may be prone
therefore to incidents of impulsive aggression. This can occur in the
context of personality disorders, dementia, intellectual disability
or other dysfunction of the central nervous system with various
aetiology. Pharmacological prevention of aggression needs to be
primarily directed at treating the underlying diseases, such as, e.g.,
cholinesterase inhibitors for neuropsychiatric symptoms in
Alzheimer’s disease [189]. In targeting high levels of impulsiveness
specifically, antiepileptics, lithium and selective serotonin reup-
take inhibitors have all been used [190]. However, only anti-
epileptics have been subject to rigorous systematic review
methodology: A Cochrane review [166] concluded that only four
antiepileptics (valproate/divalproex, carbamazepine, oxcarbaze-
pine and phenytoin) were effective, compared to placebo, in
reducing acts of impulsive aggression. For the management of
agitation and/or aggression in patients with acquired brain injury
though, another Cochrane review found some evidence for the
effectiveness of propanolol but not for carbamazepine or valproate
[191]. For Alzheimer’s disease, olanzapine and risperidone have
been found to be effective in the reduction in aggression though
they have also attracted most side effects according to a Cochrane
systematic review [192].
The body of evidence is insufficient to allow any definite
conclusion to be drawn about pharmacological interventions in
the case of patients presenting with aggression and PD. There is
sparse evidence to support the use of anticonvulsants to reduce
aggression in PD patients, as well as the intensity of subjective states
of anger, the readiness to react to anger (trait–anger) and the
tendency to direct anger outwards, and to increase in the ability to
control anger [193]. A Cochrane review on pharmacological
interventions in ASPD [194] found some evidence for the use of
nortryptiline and bromocriptine and reported on one trial which
found phenytoin to be effective in reducing impulsive aggression in
male prisoners. Some evidence supports the use of the antipsy-
chotics quetiapine [195,196], aripiprazole [197], paliperidone [198]
and the anticonvulsants divalproex extended-release [199], top-
iramate [200] and lamotrigine [201] in the preventing the aggression
among individuals with borderline personality disorder.
Clozapine warrants attention here as there is some evidence
that it might have anti-aggressive properties. It has been found to
be effective in reducing violence in patients with SSD, particularly
in treatment-resistant conditions. Reduction of the clinical severity
of ASPD has been demonstrated in detained patients with ASPD
treated with clozapine [202]. A case series in patients with
borderline PD also reported the reduction in aggression [203] and
clozapine has also been associated with reduced re-offending
compared to other antipsychotics [204]. However, a systematic
review on the subject [205], concluded that in view of a small
number of studies it remains unclear as to whether clozapine is
more effective than other antipsychotics in reducing aggression.
3.5.2.3. Pharmacological treatment of sex offenders. A Cochrane
Review of pharmacological interventions for sexoffenders identified
onlyseventrials,published over20years ago, therefore not including
newer drugs currently in use [206]. The authors concluded that their
review did not provide sufficient evidence for reducing sexual
recidivism using pharmacological interventions. Despite this such
interventions are frequently used and the guidelines published bythe World Federation of Societies of Biological Psychiatry [207]
recommend an algorithm including selective serotonin reuptake
inhibitors and antiandrogens, depending on the level of risk.
4. Conclusions
Forensic-psychiatric institutions are high-cost, low volume
services which pose significant restrictions on individuals. It is
therefore imperative that the practice of forensic psychiatry
follows the highest standards, based on the most recent scientific
evidence. In this review we summarised the evidence and available
guidance regarding expert witnessing, risk assessment, treatment
settings and interventions for MDOs. Overall, the evidence base for
forensic psychiatry is weak and future high quality trials are
urgently needed in this complex and doubly stigmatised patient
group. Nevertheless, some conclusions can be drawn for the
practice of forensic psychiatry in Europe:
- Forensic-psychiatric care produces better outcomes than
incarceration in prison alone and should therefore be the
preferred modality for interventions.
- Service organisation varies widely across Europe, including
where services are delivered (prisons, general or forensic-
psychiatric hospitals), how they are organised (e.g. levels of
security), who decides on access to and discharge from services
(governmental bodies, judiciary, medical) and admission criteria
(e.g. exclusion of certain types of individuals). There is
insufficient evidence to suggest one model of care over another
at this point, but generally care models which minimise length
of stay and restrictions and allow smooth transitions are to be
preferred. In terms of oversight, it seems important that
professionals working in forensic-psychiatric settings are able
to make decisions in the best interest of patients and not be
unduly influenced by political considerations.
- Forensic psychiatrists who give evidence in court need to be
aware of their role as independent expert. They fulfil this role to
assist the legal process and not as treating physicians.
Nevertheless, they are governed by their professional bodies
and medical ethics.
- Risk assessment is an important part of forensic psychiatry.
Structured tools should be used for this task. Those based on
structured professional judgement (SPJ) are to be preferred as
they allow the identification of treatment targets and plans for
the management of risk rather than its pure description and
prediction of future events. Due to their, at best, moderate
performance in risk prediction, practitioners should be aware of
the limitation of the tools available and not use them as sole
determinant of decision making. Protective factors should be
taken into account.
- MDOs should be directed towards and diverted into psychiatric
care early in the judicial process wherever possible.
- Community treatment orders as an approach to managing MDOs
in the community cannot currently be recommended on the
basis of available evidence.
- MDOs have a range of complex needs and evidence is often
limited as to which interventions might be effective, in
particular where comorbidities, such as substance use disorders,
exist. In designing interventions for MDOs practitioners need to
draw from the literature regarding non-offending psychiatric
patients as well as that from offending populations.
- The RNR and GLM are useful frameworks informing care
delivery and intervention programmes with some evidence
that programmes adhering to the former produce better results.
- General elements of the therapeutic milieu include the
therapeutic use of security, multidisciplinary working, patient
involvement, meaningful activities and quality of life.
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are of particular importance for MDOs.
- CBT based approaches, group and individual, focusing on
problem-solving and interpersonal skills, have the best evidence
base for the treatment of MDOs and should be preferred over
other models.
- The evidence base for interventions of sex offenders is weak and
on the basis of this evidence no psychosocial interventions can
currently be recommended for this group. Research is urgently
needed to identify effective psychological and psychosocial
interventions for these offenders.
- There is some (weak) evidence for the effectiveness of
antipsychotic agents (in particular clozapine) in reducing
aggression and for the use of mood stabilisers/antiepileptics
and antipsychotics in impulsivity.
- The pharmacological treatment for sex offenders includes SSRIs
and antiandrogens though the evidence base is weak.
- For MDOs in prisons the principle of equivalence should be
applied.
- Suicide prevention is crucial in any setting where MDOs are
detained and treated.
References
[1] Häfner H., Böker W. Mentally disordered violent offenders. Soc Psychiatry
1973;8:220–9.
[2] Swanson JW. Mental disorder, substance abuse, and community violence: an
epidemiological approach. Violence and mental disorder: developments in
risk assessment. In: Monahan J, Steadman HJ, editors. Violence and mental
disorder: developments in risk assessment. Chicago: University of Chicago
Press; 1994. p. 101–36.
[3] Steadman HJ, Mulvey EP, Monahan J, Robbins PC, Appelbaum PS, Grisso T, et al.
Violence by people discharged from acute psychiatric inpatient facilities and by
others in the same neighborhoods. Arch Gen Psychiatry 1998;55:393–401.
[4] Douglas KS, Guy LS, Hart SD. Psychosis as a risk factor for violence to others: a
meta-analysis. Psychol Bull 2009;135:679–706.
[5] Fazel S, Gulati G, Linsell L, Geddes JR, Grann M. Schizophrenia and violence:
systematic review and meta-analysis. PLoS Med 2009;6:e1000120, doi:
http://dx.doi.org/10.1371/journal.pmed.1000120.
[6] Fazel S, Lichtenstein P, Grann M, Goodwin GM, Långström N. Bipolar disorder
and violent crime: new evidence from population-based longitudinal studies
and systematic review. Arch Gen Psychiatry 2010;67:931–8.
[7] Yu R, Geddes JR, Fazel S. Personality disorders, violence, and antisocial
behavior: a systematic review and meta-regression analysis. J Personal
Disord 2012;26:775–92.
[8] Witt K, Van Dorn R, Fazel S. Risk factors for violence in psychosis: systematic
review and meta-regression analysis of 110 studies. PLoS One 2013;8(2):
e55942.
[9] McMurran M, Theodosi E. Is treatment non-completion associated with
increased reconvictionovernotreatment?Psychol CrimeLaw 2007;13:333–43.
[10] Travers R, Wakeling HC, Mann RE, Hollin CR. Reconviction following a
cognitive skills intervention: an alternative quasi-experimental
methodology. Legal Crim Psychol 2013;18:48–65.
[11] Fazel S, Zetterqvist J, Larsson H, Långström N, Lichtenstein P. Antipsychotics,
mood stabilisers, and risk of violent crime. Lancet 2014;384:1206–14.
[12] *American Academy of Psychiatry and the Law (AAPL). Ethics guidelines for
the practice of forensic psychiatry (adopted May 2005). 2005 Available at:
http://www.aapl.org/ethics.htm. Accessed 4 August 2016.
[13] Gunn J, Taylor P. Forensic psychiatry: clinical, legal and ethical issues. Boca
Raton, FL: CRC Press; 2014.
[14] Taylor PJ, Farrington DP. The psychosocial milieu of the offender. In: Gunn J,
Taylor PJ, editors. Forensic Psychiatry: Clinical, Legal and Ethical Issues.
second edition CRC Press; 2014. p. 170–85.
[15] Degl'Innocenti A, Hassing LB, Lindqvist AS, Andersson H, Eriksson L, Hanson
FH, et al. First report from the Swedish National Forensic Psychiatric Register
(SNFPR). Int J Law Psychiatry 2014;37:231–7.
[16] N. Huband, V. Furtado, S. Schel, M. Eckert, N. Cheung, E. Bulten, B. Völlm, (in
press) Characteristics and Needs of Long-stay Forensic Psychiatric Inpatients:
A Rapid Review of the Literature. Int J Forensic Ment Health.
[17] Robertson MD, Walter G. Many faces of the dual-role dilemma in psychiatric
ethics. Aust N Z J Psychiatry 2008;42:228–35.
[18] NHS institute for innovation and improvement. Enhancing engagement in
Medical Leadership. 2007 http://www.institute.nhs.uk/building_capability/
enhancing_engagement/enhancing_en gagement_in_medical_leadership.
html..
[19] Bhugra D, Ruiz P, Gupta S. Leadership in psychiatry. Chichester, UK: John
Wiley & Sons; 2013.[20] *Nedopil N. The role of forensic psychiatry in mental health systems in
Europe. Crim Behav Ment Health 2009;19:224–34.
[21] Ng LL. Forging steel from fire: emerging as a forensic psychiatrist. Acad
Psychiatry 2016;14:1–2.
[22] Istanbul Protocol. Manual on the effective investigation and documentation
of torture and other cruel, inhuman or degrading treatment or punishment.
United Nations: High Commissioner For Human Rights; 1999 http://www.
ohchr.org/Documents/Publications/training8Rev1en.pdf.
[23] Candilis PJ. The revolution in forensic ethics: narrative, compassion, and a
robust professionalism. Psychiatr Clin North Am 2009;32:423–35.
[24] Konrad N. Ethical issues in forensic psychiatry in penal and other correctional
facilities. Curr Opin Psychiatry 2010;23:467–71.
[25] Flynn G, O'Neill C, Kennedy HG. DUNDRUM-2: prospective validation of a
structured professional judgment instrument assessing priority for
admission from the waiting list for a Forensic Mental Health Hospital. BMC
Res Notes 2011;4:230, doi:http://dx.doi.org/10.1186/1756-0500-4-230.
[26] Flynn G, O'Neill C, McInerney C, Kennedy HG. The DUNDRUM-1 structured
professional judgment for triage to appropriate levels of therapeutic
security: retrospective-cohort validation study. BMC Psychiatry 2011;11:43.
[27] Davoren M, O'Dwyer S, Abidin Z, Naughton L, Gibbons O, Doyle E, et al.
Prospective in-patient cohort study of moves between levels of therapeutic
security: the DUNDRUM-1 triage security, DUNDRUM-3 programme
completion and DUNDRUM-4 recovery scales and the HCR-20. BMC
Psychiatry 2012;12:80.
[28] Salize HJ, Lepping P, Dressing H. How harmonized are we? Forensic mental
health legislation and service provision in the European Union. Crim Behav
Ment Health 2005;15:143–7.
[29] *Edworthy R, Sampson S, Völlm B. Inpatient forensic-psychiatric care: legal
frameworks and service provision in three European countries. Int J Law
Psychiatry 2016;47:18–27.
[30] www.prisonstudies.org/map/Europe. Accessed August 1, 2016.
[31] Mundt AP, Fran9ciškovic T, Gurovich I, Heinz A, Ignatyev Y, Ismayilov F, et al.
Changes in the provision of institutionalized mental health care in post-
communist countries. PLoS One 2012;7:e38490.
[32] *Chow WS, Priebe S. How has the extent of institutional mental healthcare
changed in Western Europe? Analysis of data since 1990. BMJ Open 2016;6
(4):e010188.
[33] S. Sampson, R. Edworthy, B. Völlm, (Submitted) Provisions for long-term
forensic- psychiatric care: an international comparison of 18 European
countries.
[34] Salize HJ, Dreßing H, Kief C. Placement and treatment of mentally ill
offenders–legislation and practice in EU Member States. Final Report.
Mannheim, Germany: Central Institute of Mental Health; 2005.
[35] Sugarman P, Oakley C. The evolution of secure and forensic care. J For
Psychiatr Psychol 2012;23:279–84.
[36] Heitzman J, Markiewicz I. Financing of forensic psychiatry in view of
treatment quality and threat to public safety. Psychiatr Pol 2017;51:599–608.
[37] Lal S, Adair CE. E-mental health: a rapid review of the literature. Psychiatr
Serv 2014;65:24–32.
[38] Khangura S, Konnyu K, Cushman R, Grimshaw J, Moher D. Evidence
summaries: the evolution of a rapid review approach. Syst Rev 2012;1:10.
[39] Watt A, Cameron A, Sturm L, Lathlean T, Babidge W, Blamey S, et al. Rapid
versus full systematic reviews: validity in clinical practice? ANZ J Surg
2008;78:1037–40, doi:http://dx.doi.org/10.1111/j.1445-2197.2008.04730.x.
[40] Eronen M, Seppänen A, Kotilainen I. Forensic psychiatry in Finland. Nord
Psychiatrist 2012;1:20–1.
[41] Konrad N, Völlm B. Forensic psychiatric expert witnessing within the
criminal justice system in Germany. Int J Law Psychiatry 2014;37:149–54.
[42] Rix K. Expert psychiatric evidence. London: The Royal College of
Psychiatrists; 2011.
[43] Boetticher A, Kröber HL, Müller-Isberner R, Böhm KM, Müller-Metz R, Wolf T.
Mindestanforderungen für Prognosegutachten. Forens Psychiatr Psycholo
Kriminol 2017;1:90–100.
[44] Nederlandse Vereniging voor Psychiatrie. Richtlijn psychiatrisch onderzoek
en rapportage in strafzaken. Enschede: Nederlandse Vereniging voor
Psychiatrie; 2012.
[45] Terveyden Ja Hyvinvoinnin Laitos. 2011 http://www.julkari.fi/bitstream/
handle/10024/80084/f53130ab-3b97-40da-8e9d-6dce6486b8e6.pdf?
sequence=1..
[46] *http://www.wpanet.org/uploads/Sections/Forensic_Psychiatry/wpa-IME-
guidelinesRev2014final.pdf.
[47] Taylor PJ, Graf M, Schanda H, Völlm B. The treating psychiatrist as expert in
the courts: is it necessary or possible to separate the roles of physician and
expert? Crim Behav Ment Health 2012;22:271–92.
[48] Gottfried ED, Schenk AM, Vitacco MJ. Retrospectively assessing for feigning in
criminal responsibility evaluations: recommendations for clinical practice. J
For Psychol Pract 2016;16:118–28.
[49] Meyer GJ, Finn SE, Eyde LD, Kay GG, Moreland KL, Dies RR, et al. Psychological
testing and psychological assessment: a review of evidence and issues. Am
Psychol 2001;56:128–65.
[50] *Eastman N, Riordan D, Adshead G. Ethical roles, relationships and duties of
forensic mental health clinicians. In: Bartlett A, McGauley G, editors. Forensic
mental health: Concepts, systems, and practice. Oxford: Oxford University
Press; 2010. p. 313–21.
[51] Schanda H. Problems in the treatment of mentally ill offenders–a problem of
general psychiatry? Psychiatr Prax 2000;27:S72–6.
B.A. Völlm et al. / European Psychiatry 51 (2018) 58–73 71[52] Andrews DA, Bonta J. Rehabilitating criminal justice policy and practice.
Psychol Public Policy Law 2010;16:39–55.
[53] Fazel S, Singh JP, Doll H, Grann M. Use of risk assessment instruments to
predict violence and antisocial behaviour in 73 samples involving 24 827
people: systematic review and meta-analysis. BMJ 2012345:, doi:http://dx.
doi.org/10.1136/bmj.e4692.
[54] Philipse MW. Predicting criminal recidivism: empirical studies and clinical
practice in forensic psychiatry. Enschede: Febodruk; 2005.
[55] Singh JP, Desmarais SL, Hurducas C, Arbach-Lucioni K, Condemarin C, Dean K,
et al. International perspectives on the practical application of violence risk
assessment: a global survey of 44 countries. Int J Forensic Ment Health
2014;13:193–206.
[56] Heilbrun K, Yasuhara K, Shah S. Violence risk assessment tools. In: Otto RK,
Douglas KS, editors. Handbook of violence risk assessment. Taylor & Francis
Group; 2010. p. 1–17.
[57] Shiina A. Risk assessment and management of violence in patients with
mental disorders: a review. J Forensic Legal Investig Sci 20151(002) http://
www.heraldopenaccess.us/fulltext/Forensic-Legal-&-Investigative-
Sciences/Risk-Assessment-and-Management-of-Violence-in-Patients-with-
Mental-Disorders-A-Review.pdf..
[58] Wong SC, Gordon A. The validity and reliability of the violence risk scale: a
treatment-friendly violence risk assessment tool. Psychol Public Policy Law
2006;12:279–309.
[59] Douglas KS, Hart SD, Webster CD, Belfrage H. HCR-20V3: Assessing risk of
violence – User guide. Burnaby, Canada: Mental Health, Law, and Policy
Institute, Simon Fraser University; 2013.
[60] Nicholls TL, Petersen KL, Pritchard MM. Comparing preferences for actuarial
versus structured professional judgment violence risk assessment
measures across five continents: to what extent is practice keeping pace
with science? In: Singh JP, Bjørkly S, Fazel S, editors. International
Perspectives on Violence Risk Assessment. Oxford: Oxford University Press;
2016. p. 127–49.
[61] Coid J, Yang M, Ullrich S, Zhang T, Sizmur S, Roberts C, et al. Gender
differences in structured risk assessment: comparing the accuracy of five
instruments. J Consult Clin Psychol 2009;77:337–48.
[62] Klepfisz G, Daffern M, Day A. Understanding dynamic risk factors for
violence. Psychol Crime Law 2015;22:124–37.
[63] Coid JW, Kallis C, Doyle M, Shaw J, Ullrich S. Identifying causal risk factors for
violence among discharged patients. PLoS One 2015;10(11):e0142493.
[64] * Fitzpatrick R, Chambers J, Burns T, Doll H, Fazel S, Jenkinson C, et al. A
systematic review of outcome measures used in forensic mental health
research with consensus panel opinion. Health Technol Assess (Winchester,
England) 2010;14(18):1–94.
[65] *Hurducas CC, Singh JP, de Ruiter C, Petrila J. Violence risk assessment tools:
a systematic review of surveys. Int J Forensic Ment Health 2014;13(3):181–92.
[66] Webster CD, Douglas KS, Eaves D, Hart SD. HCR- 20: Assessing Risk for
Violence. Version 2. Burnaby, BC: Simon Fraser University, Mental Health,
Law, and Policy Institute; 1997.
[67] Hare RD. The Hare Psychopathy Checklist-Revised. Toronto, ON: Multi-
Health Systems; 2003.
[68] Singh JP, Grann M, Fazel S. A comparative study of violence risk assessment
tools: a systematic review and metaregression analysis of 68 studies
involving 25,980 participants. Clin Psychol Rev 2011;31:499–513.
[69] *Craig LA, Beech AR. Towards a guide to best practice in conducting actuarial
risk assessments with sex offenders. Aggression Violent Behav 2010;15:278–
93.
[70] *Hanson RK, Morton-Bourgon KE. The accuracy of recidivism risk
assessments for sexual offenders: a meta-analysis of 118 prediction
studies. Psychol Assess 2009;21:1–21.
[71] Singh JP, Fazel S, Gueorguieva R, Buchanan A. Rates of violence in patients
classified as high risk by structured risk assessment instruments. Br J
Psychiatry 2014;204:180–7.
[72] *Dolan M, Völlm B. Antisocial personality disorder and psychopathy in
women: a literature review on the reliability and validity of assessment
instruments. Int J Law Psychiatry 2009;32:2–9.
[73] *Morrissey C. Use of risk assessment tools for people with intellectual
disability: the latest evidence. Eur Psychiatry 2016;33:S38.
[74] *Barnao M. The Good Lives Model tool kit for mentally disordered offenders. J
Forensic Pract 2013;15:157–70.
[75] Rogers R. The uncritical acceptance of risk assessment in forensic practice.
Law Hum Behav 2000;24:595–605.
[76] de Vries Robbé M, Mann RE, Maruna S, Thornton D. An exploration of
protective factors supporting desistance from sexual offending. Sexual
Abuse: J Res Treat 2015;27:16–33.
[77] de Vogel V, de Ruiter C, Bouman Y, de Vries Robbé M. SAPROF. Guidelines for
the assessment of protective factors for violence risk. 2nd ed. Utrecht: Van
der Hoeven Stichting; 2012.
[78] *de Vries Robbé M, Willis GM. Assessment of protective factors in clinical
practice. Aggression Violent Behav 2017;32:55–63.
[79] de Vries Robbé M, de Vogel V, Koster K, Bogaerts S. Assessing protective
factors for sexually violent offending with the SAPROF. Sexual Abuse: J Res
Treat 2015;27:51–70.
[80] Abbiati M, Azzola A, Palix J, Gasser J, Moulin V. Validity and predictive
accuracy of the structured assessment of protective factors for violence risk
in criminal forensic evaluations: a Swiss cross-validation retrospective study.
Crim Justice Behav 2017;44:493–510.[81] O'Shea LE, Dickens GL. Performance of protective factors assessment in risk
prediction for adults: systematic review and meta-analysis. Clin Psychol Sci
Pract 2016;23:126–38.
[82] *Troquete NAC, van den Brink RH, Beintema H, Mulder T, van Os TW,
Schoevers RA, et al. Risk assessment and shared care planning in out-patient
forensic psychiatry: cluster randomised controlled trial. Br J Psychiatry
2013;202:365–71.
[83] *Scott DA, McGilloway S, Dempster M, Browne F, Donnelly M. Effectiveness of
criminal justice liaison and diversion services for offenders with mental
disorders: a review. Psychiatr Serv 2013;64:843–9.
[84] Parsonage M, Khanoum H, Rutherford M, Sidhu M, Smith C. Diversion: A
Better Way for Criminal Justice and Mental Health. London: Sainsbury Centre
for Mental Health; 2009 http://www.ohrn.nhs.uk/resource/policy/
DiversionSCMH.pdf..
[85] *Hartford K, Carey R, Mendonca J. Pre-arrest diversion of people with mental
illness: literature review and international survey. Behav Sci Law 2006;24:845–
56.
[86] Brooker C, Fox C, Barrett P, Syson-Nibbs L. A health needs assessment of
offenders on probation caseloads in Nottinghamshire and Derbyshire-report
of a pilot study. University of Lincoln; 2008 http://eprints.lincoln.ac.uk/2534/
1/Probation_HNA.pdf..
[87] Howard P. The Offender Assessment System: an evaluation of the second
pilot. Home Office; 2006 http://webarchive.nationalarchives.gov.uk/
20110314171826/http:/rds.homeoffice.gov.uk/rds/pdfs06/r278.pdf..
[88] Draine J, Salzer MS, Culhane DP, Hadley TR. Role of social disadvantage in
crime, joblessness, and homelessness among persons with serious mental
illness. Psychiatr Serv 2002;53:565–73.
[89] Kaul A, Völlm B, et al. Current ethical challenges in prison psychiatry in
England and Wales. In: Konrad N, editor. Ethical Issues in Prison Psychiatry.
Netherlands: Springer; 2013. p. 367–88.
[90] Pickersgill M. How personality became treatable: the mutual constitution of
clinical knowledge and mental health law. Soc Stud Sci 2013;43:30–53.
[91] *Jennings JL. Does assertive community treatment work with forensic
populations? Review and recommendations. Open Psychiatry J 2009;3:13–9.
[92] *Marquant T, Sabbe B, Van Nuffel M, Goethals K. Forensic assertive
community treatment: a review of the literature. Community Ment Health
J 2016;52:873–81.
[93] *Burns T. Community treatment orders: state of the evidence. East Asian Arch
Psychiatry 2013;23(2):35–6.
[94] Maughan D, Molodynski A, Rugkåsa J, Burns T. Community treatment orders:
a systematic review of clinical outcomes. Soc Psychiatry Psychiatr Epidemiol
2014;49:651–63.
[95] Kisely SR, Campbell LA, Preston NJ. Compulsory community and involuntary
outpatient treatment for people with severe mental disorders. Cochrane
Database Syst Rev. 2011;CD004408.
[96] *Fazel S, Fiminska Z, Cocks C, Coid J. Patient outcomes following discharge
from secure psychiatric hospitals: systematic review and meta-analysis. Br J
Psychiatry 2016;208:17–25.
[97] Bonta J, Law M, Hanson K. The prediction of criminal and violent recidivism
among mentally disordered offenders: a meta-analysis. Psychol Bull
1998;123:123–42.
[98] Ministry of Justice. Statistics of mentally disordered offenders 2008 England
and Wales, Statistics Bulletin. London: Ministry of Justice; 2010.
[99] *Völlm B, Edworthy R, Holley J, Talbot E, Majid S, Duggan C, et al. A mixed-
methods study exploring the characteristics and needs of long-stay patients
in high and medium secure settings in England: implications for service
organisation. Health Serv Deliv Res 20175(11).
[100] *Völlm B. Assessment and management of dangerous and severe personality
disorders. Curr Opin Psychiatry 2009;22:501–6.
[101] Kennedy HG. Therapeutic uses of security: mapping forensic mental health
services by stratifying risk. Adv Psychiatric Treat 2002;8:433–43.
[102] *Tapp J, Warren F, Fife-Schaw C, Perkins D, Moore E. Essential elements of
treatment and care in high secure forensic inpatient services: an expert
consensus study. J Forensic Pract 2016;18:189–203.
[103] *Tapp J, Perkins D, Warren F, Fife-Schaw C, Moore E. A critical analysis of
clinical evidence from high secure forensic inpatient services. Int J Forensic
Ment Health 2013;12:68–82.
[104] Fazel S, Danesh J. Serious mental disorder in 23 000 prisoners: a systematic
review of 62 surveys. Lancet 2002;359:545–50.
[105] Fazel S, Seewald K. Severe mental illness in 33 588 prisoners worldwide:
systematic review and meta-regression analysis. Br J Psychiatry
2012;200:364–73.
[106] Fazel S, Grann M, Kling B, Hawton K. Prison suicide in 12 countries: an
ecological study of 861 suicides during 2003–2007. Soc Psychiatry Psychiatr
Epidemiol 2011;46:191–5.
[107] Mann RE. Sex offenders in prison. In: Jewkes Y, Crewe B, Bennett J, editors.
Handbook on prisons. London: Routledge; 2016. p. 246–64.
[108] Goomany A, Dickinson T. The influence of prison climate on the mental health
of adult prisoners: a literature review. J Psychiatr Ment Health Nurs
2015;22:413–22.
[109] Salize HJ, Dreßing H, Kief C. Mentally Disordered Persons in European Prison
Systems—Needs, Programmes and Outcome (EUPRIS) Final Report – October
31, 2007. 2007.
[110] *Gee J, Bertrand-Godfrey B. Researching the psychological therapies in
prison: considerations and future recommendations. Int J Prisoner Health
2014;10:118–31.
72 B.A. Völlm et al. / European Psychiatry 51 (2018) 58–73[111] *United Nations Standard Minimum Rules for the Treatment of Prisoners.
2015 https://www.unodc.org/documents/justice-and-prison-reform/GA-
RESOLUTION/E_ebook.pdf..
[112] *UN Convention on the Rights of Persons with Disabilities. 2006 https://
www.un.org/development/desa/disabilities/convention-on-the-rights-of-
persons-with-disabilities/convention-on-the-rights-of-persons-with-
disabilities-2.html..
[113] *Kelk C. Recommendation No. R (98) 7 of the committee of ministers to
member states concerning the ethical and organisational aspects of health
care in prison. Eur J Health Law 1999;6:265–78.
[114] *Council of Europe European Prison Rules (Recommendation Rec[2006]2).
2006 https://rm.coe.int/16806f3d4f..
[115] *The European Committee for the Prevention of Torture and Inhuman or
Degrading Treatment or Punishment. 2017 https://www.coe.int/en/web/cpt/
home..
[116] *World Medical Association (Declaration of Tokyo. 1975 https://www.wma.
net/what-we-do/medical-ethics/declaration-of-tokyo/.
[117] *Declaration of Hawaii: declaration adopted unanimously by the general
assembly of the world psychiatric association at the sixth world congress of
psychiatry, 1977. BMJ 1977;2(6096)1204–5 Retrieved from http://www.jstor.
org/stable/20416582.
[118] *International Council of Prison Medical Services. Oath of Athens. 1979 www.
medekspert.az/ru/chapter1/resources/The_Oath_of_Athens.pdf..
[119] *http://wpanet.org/uploads/Sections/Forensic_Psychiatry/CONSENSUS-
PAPER-PRISON-PSYCHIATRYfinal.pdf. Accessed August 7, 2016.
[120] *Konrad N, Arboleda-Florez J, Jager AD, Naudts K, Taborda J, Tataru N.
Consensus paper: prison psychiatry. Int J Prisoner Health 2007;3:111–3.
[121] Tort-Herrando V, Van Lier EBML, Olive-Albitzur AE, Hulsbos HPAJ, Muro-
Alvarez A. The use of coercion in prison settings. In: Völlm B, Nedopil N,
editors. The Use of Coercive Measures in Forensic Psychiatric Care.
Switzerland: Springer International Publishing; 2016. p. 209–27.
[122] MøllerL,GathererA, Jürgens R,StöverH,NikogosianH. Healthinprisons:a WHO
guide to the essentials in prison health. WHO Regional Office Europe; 2007
http://www.euro.who.int/__data/assets/pdf_file/0009/99018/E90174.pdf..
[123] Konrad N, Daigle MS, Daniel AE, Dear GE, Frottier P, Hayes LM, et al.
Preventing suicide in prisons, part I: recommendations from the
International Association for Suicide Prevention Task Force on suicide in
prisons. Crisis 2007;28:113–21.
[124] Blackburn R. What works with mentally disordered offenders. Psychol Crime
Law 2004;10:297–308.
[125] Martinson R. What works? Questions and answers about prison reform. The
Public Interest 1974;35:22–54.
[126] Hollin CR. To treat or not to treat? An historical perspective. In: Hollin C,
editor. The essential handbook of offender assessment and treatment.
Chichester, UK: Wiley; 2004. p. 1–13.
[127] Quinsey VL. Assessment of the treatability of forensic patients. Behav Sci Law
1988;6:443–52.
[128] Andrews DA, Bonta J, Hoge RD. Classification for effective rehabilitation:
rediscovering psychology. Crim Justice Beh 1990;17:19–52.
[129] *Morgan RD, Flora DB, Kroner DG, Mills JF, Varghese F, Steffan JS. Treating
offenders with mental illness: a research synthesis. Law Hum Behav
2012;36:37–50.
[130] *Duncan EA, Nicol MM, Ager A, Dalgleish L. A systematic review of structured
group interventions with mentally disordered offenders. Crim Behav Ment
Health 2006;16:217–41.
[131] Marshall WL. Manualization: a blessing or a curse? J Sexual Aggression
2009;15:109–20.
[132] Ward T, Stewart CA. The treatment of sex offenders: risk management and
good lives. Prof Psychol Res Pract 2003;34:353–60.
[133] Ward T, Gannon TA. Rehabilitation, etiology, and self-regulation: the
comprehensive good lives model of treatment for sexual offenders.
Aggression Violent Beh 2006;11:77–94.
[134] *Barnao M, Ward T. Sailing uncharted seas without a compass: a review of
interventions in forensic mentalhealth. Aggression ViolentBeh 2015;22:77–86.
[135] Andrews DA, Bonta J, Wormith JS. The risk-need-responsivity (RNR) model
does adding the good lives model contribute to effective crime prevention?
Crim Justice Beh 2011;38:735–55.
[136] *McGuire J. A review of effective interventions for reducing aggression and
violence. Philos Trans R Soc Lond B Biol Sci 2008;363:2577–97.
[137] *Cure S, Chua WL, Duggan L, Adams C. Randomised controlled trials relevant
to aggressive and violent people, 1955–2000: a survey. Br J Psychiatry
2005;186(3):185–9.
[138] Rampling J, Furtado V, Winsper C, Marwaha S, Lucca G, Livanou M, et al. Non-
pharmacological interventions for reducing aggression and violence in
serious mental illness: a systematic review and narrative synthesis. Eur
Psychiatry 2016;34:17–28.
[139] *Cullen A, Clarke A, Kuipers E, Hodgins S, Dean K, Fahy T. A multisite
randomised trial of a cognitive skills programme for male mentally
disordered offenders: social-cognitive outcomes. Psychol Med 2012;42:557–
69.
[140] *Ahmed AO, Hunter KM, Goodrum NM, Batten NJ, Birgenheir D, Hardison E,
et al. A randomized study of cognitive remediation for forensic and mental
health patients with schizophrenia. J Psychiatr Res 2015;68:8–18.
[141] *Coutinho BV, Hansen AL, Waage L, Hillecke TK, Koenig J. Music making
interventions with adults in the forensic setting–a systematic review of the
literature–part I: group interventions. Music Med 2015;7(3):40–53.[142] *Coutinho BV, Hansen AL, Waage L, Hillecke TK, Koenig J. Music making
interventions with adults in the forensic setting–a systematic review of the
literature–part II: case studies and good vibrations. Music Med 2015;7
(4):50–71.
[143] *Bartlett A, Jhanji E, White S, Anne Harty M, Scammell J, Allen S. Interventions
with women offenders: a systematic review and meta-analysis of mental
health gain. J For Psychiatr Psychol 2015;26:133–65.
[144] *Moloney KP, Moller LF. Good practice for mental health programming for
women in prison: reframing the parameters. Public Health 2009;123:431–3.
[145] Marques JK, Day DM, Nelson C, West MA. Effects of cognitive-behavioural
treatment on sex offender recidivism. Crim Justice Behav 1994;21:28–54.
[146] *Dennis JA, Khan O, Ferriter M, Huband N, Powney MJ, Duggan C.
Psychological interventions for adults who have sexually offended or are
at risk of offending. (CD007507; Cochrane Database of Systematic Reviews
Issue 12). Chichester, UK: John Wiley & Sons; 2012.
[147] *Marques JK, Wiederanders M, Day DM, Nelson C, van Ommeren A. Effects of
a relapse prevention program on sexual recidivism: final results from
California’s sex offender treatment and evaluation project (SOTEP). Sexual
Abuse: J Res Treat 2005;17:79–107.
[148] Beech A, Freemantle N, Power C, Fisher D. An examination of potential biases
in research designs used to assess the efficacy of sex offender treatment. J
Aggress Confl Peace Res 2015;7:204–22.
[149] Grønnerød C, Grønnerød JS, Grøndahl P. Psychological treatment of sexual
offenders against children a meta-analytic review of treatment outcome
studies. Trauma Violence Abuse 2015;16:280–90.
[150] Mews A, Di Bella L, Purver M. Impact evaluation of the prison-based Core Sex
Offender Treatment Programme. London: Ministry of Justice; 2017.
[151] *Yoon IA, Slade K, Fazel S. Outcomes of psychological therapies for prisoners
with mental health problems: a systematic review and meta-analysis. J
Consult Clin Psychol 2017;85:783–802.
[152] *DugganC,HubandN,SmailagicN,FerriterM,AdamsC.Theuseofpsychological
treatments for people with personality disorder: a systematic review of
randomized controlled trials. Personal Ment Health 2007;1:95–125.
[153] Wilson HA. Can antisocial personality disorder be treated? A meta-analysis
examining the effectiveness of treatment in reducing recidivism for
individuals diagnosed with ASPD. Int J For Ment Health 2014;13:36–46.
[154] *National Institute for Health and Clinical Excellence. Antisocial Personality
Disorder: Treatment, Management and Prevention. London: NICE; 2009 URL:
www.nice.org.uk/guidance/cg77..
[155] *National Institute for Health and Clinical Excellence. Personality disorders:
borderline and antisocial: Quality standard. London: NICE; 2015 URL: www.
nice.org.uk/guidance/qs88..
[156] *Emmelkamp PM, Vedel E. Psychological treatments for antisocial
personality disorder: where is the evidence that group treatment and
therapeutic community should be recommended? Personal Ment Health
2010;4:30–3.
[157] McMurran M, Huband N, Overton E. Non-completion of personality disorder
treatments: a systematic review of correlates, consequences, and
interventions. Clin Psychol Rev 2010;30:277–87.
[158] *de Ruiter C, Chakhssi F, Bernstein DP. Treating the untreatable psychopath.
In: Gacono CB, editor. The clinical and forensic assessment of psychopathy: A
practitioner's guide. 2nd ed. New York: Routledge/Taylor & Francis Group;
2016. p. 388–402.
[159] Burns T, Yiend J, Fahy T, Fitzpatrick R, Rogers R, Fazel S, et al. Treatments for
dangerous severe personality disorder (DSPD). J For Psychiatr Psychol
2011;22:411–26.
[160] Tyrer P, Duggan C, Cooper S, Tyrer H, Swinson N, Rutter D. The lessons and
legacy of the programme for dangerous and severe personality disorders.
Personal Ment Health 2015;9:96–106.
[161] Völlm B, Konappa N. The dangerous and severe personality disorder
experiment–review of empirical research. Crim Behav Ment Health
2012;22:165–80.
[162] Joseph N, Benefield N. A joint offender personality disorder pathway
strategy: an outline summary. Crim Behav Ment Health 2012;22:210–7.
[163] *Knabb JJ, Welsh RK, Graham-Howard ML. Treatment alternatives for
mentally disordered offenders: a literature review. Psychol 2011;2:122–31.
[164] Papadopoulos C, Ross J, Stewart D, Dack C, James K, Bowers L. The antecedents
of violence and aggression within psychiatric in-patient settings. Acta
Psychiatr Scand 2012;125:425–39.
[165] *National Institute for Health and Care Excellence (2015) Violence and
Aggression: Short-term management in mental health, health and
community settings. NICE Guideline NG10; https://www.nice.org.uk/
guidance/ng10.
[166] Huband N, Ferriter M, Nathan R, Jones H. Antiepileptics for aggression and
associated impulsivity. Cochrane Database Syst Rev 2010;2:CD003499.
[167] Parker C, Khwaja MG. What is new in rapid tranquillisation? J Psychiatr
Intensive Care 2011;7:91–101.
[168] Mohr WK, Petti TA, Mohr BD. Adverse effects associated with physical
restraint. Can J Psychiatry 2003;48:330–7.
[169] Holloman Jr GH, Zeller SL. Overview of project BETA: best practices in
evaluation and treatment of agitation. West J Emerg Med 2012;13:1–2.
[170] Wilson MP, Pepper D, Currier GW, Holloman Jr GH, Feifel D. The
psychopharmacology of agitation: consensus statement of the American
Association for Emergency Psychiatry project Beta psychopharmacology
workgroup. West J Emerg Med 2012;13:26–34.
[171] www.nice.org.uk/guidance/CG25.
B.A. Völlm et al. / European Psychiatry 51 (2018) 58–73 73[172] Garriga M, Pacchiarotti I, Kasper S, Zeller SL, Allen MH, Vázquez G, et al.
Assessment and management of agitation in psychiatry: expert consensus.
World J Biol Psychiatry 2016;17:86–128.
[173] https://www.gov.uk/government/uploads/system/uploads/
attachment_data/file/ 435512/MHA_Code_of_Practice.PDF.
[174] Raboch J, Kališová L, Nawka A, Kitzlerová E, Onchev G, Karastergiou A, et al.
Use of coercive measures during involuntary hospitalization: findings from
ten European countries. Psychiatr Serv 2010;61:1012–7.
[175] Whittington R, Bowers L, Nolan P, Simpson A, Neil L. Approval ratings of
inpatient coercive interventions in a national sample of mental health service
users and staff in England. Psychiatr Serv 2009;60:792–8.
[176] Igoumenou A, Kallis C, Coid J. Treatment of psychosis in prisons and violent
recidivism. Br J Psychiatry Open 2015;1:149–57.
[177] Erb M, Hodgins S, Freese R, Müller-Isberner R, Jöckel D. Homicide and
schizophrenia: maybe treatment does have a preventive effect. Crim Behav
Ment Health 2001;11:6–26.
[178] Swanson JW, Swartz MS, Elbogen EB. Effectiveness of atypical antipsychotic
medications in reducing violent behavior among persons with schizophrenia
in community-based treatment. Schizophr Bull 2004;30:3–20.
[179] Brieden T, Ujeyl M, Naber D. Psychopharmacological treatment of aggression
in schizophrenic patients. Pharmacopsychiatry 2002;35:83–9.
[180] Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. Expert consensus
panel for behavioral emergencies (2005). The expert consensus guideline
series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005;11
(Suppl. 1):5–108.
[181] Victoroff J, Coburn K, Reeve A, Sampson S, Shillcutt S. Pharmacological
management of persistent hostility and aggression in persons with
schizophrenia spectrum disorders: a systematic review. J Neuropsychiatry
Clin Neurosci 2014;26:283–312.
[182] National Institute for Health and Care Excellence (2015) https://www.nice.
org.uk/Media/Default/newsletter/eyes-on-evidence-october-2015.pdf.
[183] O'Reilly K, O'Connell P, Donohoe G, Coyle C, O'Sullivan D, Azvee Z, et al.
Anticholinergic burden in schizophrenia and ability to benefit from
psychosocial treatment programmes: a 3-year prospective cohort study.
Psychol Med 2016;46:3199–211.
[184] Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The
cognitive cost of anticholinergic burden: decreased response to cognitive
training in schizophrenia. Am J Psychiatry 2009;166:1055–62.
[185] Gray R, David A, Quatro Research Group. Adherence therapy manual: Version
IV. 2003 Unpublished manuscript.
[186] *Cavezza C, Aurora M, Ogloff JR. The effects of an adherence therapy approach
in a secure forensic hospital: a randomised controlled trial. J For Psychiatr
Psychol 2013;24:458–78.
[187] Rezansoff SN, Moniruzzaman A, Fazel S, McCandless L, Somers JM. Adherence
to antipsychotic medication and criminal recidivism in a Canadian provincial
offender population. Schizophr Bull 2017;43:1002–10.
[188] *Tsopelas C, Tzeferakos G, Kotsiouba I, Kalemi G, Douzenis A. Use of long
acting injectables in mentally disordered offenders. Eur
Neuropsychopharmacology 2016;26:S520–521.
[189] Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for
the symptomatic treatment of dementia: the Canadian Consensus
Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers
Res Ther 2013;5(1):S5.
[190] Felthous AR, Lake SL, Rundle BK, Stanford MS. Pharmacotherapy of impulsive
aggression: a quality comparison of controlled studies. Int J Law Psychiatry
2013;36:258–63.[191] Fleminger S, Greenwood RR, Oliver DL. Pharmacological management for
agitation and aggression in people with acquired brain injury. Cochrane
Database Syst Rev. 2006;4:CD003299.
[192] Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and
psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;1:
CD003476.
[193] Duggan C, Huband N, Smailagic N, Ferriter M, Adams C. The use of
pharmacological treatments for people with personality disorder: a
systematic review of randomized controlled trials. Personal Ment Health
2008;2:119–70.
[194] *Khalifa N, Duggan C, Stoffers J, Huband N, Völlm BA, Ferriter M, et al.
Pharmacological interventions for antisocial personality disorder. Cochrane
Database Syst Rev 2010;8:CD007667.
[195] Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the
treatment of borderline personality disorder: a pilot study. J Clin Psychiatry
2006;67:1042–6.
[196] Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline
personality disorder. World J Biol Psychiatry 2003;4:42–4.
[197] Nickel MK, Muehlbacher M, Nickel C, Kettler C, Gil FP, Bachler E, et al.
Aripiprazole in the treatment of patients with borderline personality
disorder: a double-blind, placebo-controlled study. y. Am J Psychiatr
2006;163:833–8.
[198] Bellino S, Bozzatello P, Rinaldi C, Bogetto F. Paliperidone ER in the treatment
of borderline personality disorder: a pilot study of efficacy and tolerability.
Depress Res Treat 2011, doi:http://dx.doi.org/10.1155/2011/680194.
[199] Simeon D, Baker B, Chaplin W, Braun A, Hollander E. An open-label trial of
divalproex extended-release in the treatment of borderline personality
disorder. CNS Spectr 2007;12:439–43.
[200] Nickel MK, Loew TH. Treatment of aggression with topiramate in male
borderline patients, part II: 18-month follow-up. Eur Psychiatry
2008;23:115–7.
[201] Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, et al.
Lamotrigine treatment of aggression in female borderline-patients: a
randomized, double-blind, placebo-controlled study. J Psychopharmacol
2005;19:287–91.
[202] *Brown D, Larkin F, Sengupta S, Romero-Ureclay JL, Ross CC, Gupta N, et al.
Clozapine: an effective treatment for seriously violent and psychopathic men
with antisocial personality disorder in a UK high-security hospital. CNS
Spectr 2014;19:391–402.
[203] Frogley C, Anagnostakis K, Mitchell S, Mason F, Taylor D, Dickens G, et al. A
case series of clozapine for borderline personality disorder. Ann Clin
Psychiatry 2013;25:125–34.
[204] Mela M, Depiang G. Clozapine's effect on recidivism among offenders with
mental disorders. J Am Acad Psychiatry Law 2016;44:82–90.
[205] Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the
evidence of clozapine's anti-aggressive effects. Int J
Neuropsychopharmacology 2012;15:1351–71.
[206] Khan O, Ferriter M, Huband N, Powney MJ, Dennis JA, Duggan C.
Pharmacological interventions for those who have sexually offended or
are at risk of offending. Cochrane Database Syst Rev 2015;2:CD007989.
[207] Thibaut F, Bradford JM, Briken P, De La Barra F, Häßler F, Cosyns P. The World
Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the
treatment of adolescent sexual offenders with paraphilic disorders. World J
Biol Psychiatry 2016;17:2–38.
